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Foreword
On behalf of the National Hepatitis C Database Steering Committee, I am very pleased to introduce the 
2015 report from the National Hepatitis C Database. This is the fifth report to be produced from the 
database. It is based on information collected during the years 2010 – 2013 inclusive and describes the 
main findings from this data. 
2014 was a very significant year in that it marked 20 years since the announcement by the then Blood 
Transfusion Service Board that anti-D immunoglobulin, which was known to have been infected with 
the hepatitis C virus, had been administered in Ireland to many women. In the months and years that 
followed, many individuals including men, women and children in Ireland were found to have been 
infected with hepatitis C through the receipt of contaminated blood, anti-D and other blood products. 
Since 1994 we have seen the establishment of eight designated centres of care in the hospital setting, 
in addition to many other services for those individuals infected with hepatitis C through contaminated 
blood and blood products. It is now 10 years since the National Hepatitis C Database was established. 
The database has allowed us to track the progression of the hepatitis C virus so that we can continue to 
learn more about the disease and the population affected. Information gained through the database has 
been invaluable both in terms of looking at how the virus behaves over time and how people respond to 
treatment, and also in terms of helping us to know what services will be needed in the future. 
I would like to acknowledge the work of Dr Lelia Thornton and her colleagues in the Health Protection 
Surveillance Centre who manage the database. This report presents four years of data relating to the 
years 2010 to 2013 and includes some initial data on patients who have undergone anti-viral therapy using 
the new triple therapy containing direct acting anti-viral agents. There have been huge developments in 
the area of therapeutic drug treatment for hepatitis C in the last number of years and we are now entering 
into an era where complete eradication of the hepatitis C virus is a real possibility. 
Ireland’s cohort of patients who were infected through contaminated blood and blood products are of 
particular interest as most people’s date of infection is known and so therefore the behaviour of the 
virus and its impact over a period of time can be closely monitored. Therefore I would like to thank most 
sincerely all those who have given their consent to be included in the database and also those who 
have actively encouraged and continue to encourage participation through the hepatology units and 
the patient support groups. Over three quarters of those known to have been infected with hepatitis C 
through contaminated blood and blood products have their information included in the database which 
really improves the level of quality data that can be collected and then used when monitoring disease 
progression and the impact of treatment. 
The collection of this data will continue to be of vital importance in the coming years, especially with the 
advancements in treatments available to people with hepatitis C. We already know from the existing data 
that the success rate for those who have been on treatment is high among the Irish population. Although 
many of the participants in the database do not show evidence of having liver disease, a significant 
number of those with chronic infection have developed serious liver disease including cirrhosis and liver 
cancer, some of whom have died. 
We look forward to continuing to work with the project over the coming years and in particular to 
analysing the data which will emerge at a time when treatments are constantly advancing and greatly 
improving the outcomes for those who are living with the disease. 
Michele Tait
Chair 
National Hepatitis C Database Steering Committee
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Executive Summary
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world. 
Hepatitis C virus (HCV) is transmitted by blood and now occurs primarily through injecting drug use. 
Transfusion-related HCV infection is rare since the introduction of routine screening of blood for HCV 
antibodies in the early 1990s.
Between 55% and 85% of those infected develop chronic infection and are at risk of progressive 
liver disease. Up to 20% of chronically infected individuals will develop cirrhosis of the liver over a 
20 to 25 year period. Approximately 3% to 4% of patients with cirrhosis will develop hepatocellular 
carcinoma (HCC) per year. 
There have been major advances in hepatitis C treatments in recent years with the arrival of direct 
acting antivirals which have been shown to achieve very high rates of viral clearance.
The National Hepatitis C Database was set up in 2004 to collect data on people infected with HCV 
through the receipt of contaminated blood and blood products in Ireland. Approximately 1,700 
people were infected through anti-D immunoglobulin, blood transfusion, blood clotting factors or 
treatment for renal disease. The purpose of the database project is to follow the natural history of 
infection, evaluate the outcomes of treatment, provide information for planning of services, and 
serve as a resource for research. Information is gathered from the participants’ medical records in 
the eight participating hepatology units. This report is based on the fifth round of data collection 
and includes data on database participants up to the end of 2013.
Main findings
Profile of participants
•  There are 1,320 database participants, a participation rate of 77%.
•  1,060 were still alive at the end of 2013.
•  The source of infection in participants was anti-D immunoglobulin (61%), blood transfusion or 
treatment for renal disease (26%) and blood clotting factors (13%).
• The average age at last follow-up was 60 years.
• Participants included 1025 females and 295 males.
• The average time interval from infection to last follow-up was 32 years.
Hepatitis C status
•  The spontaneous viral clearance rate in this population is between 20% and 36% (depending on 
whether participants with no confirmatory antibody results are included in the denominator).
•  390 database participants (36.8%) were still alive and chronically infected at the end of 2013, at an 
average age of 63 years.
•  261 of these were infected through anti-D, 99 through blood transfusion and 28 through blood 
clotting factors.
•  The most common genotype in participants is genotype 1 (77%), followed by genotype 3 (18%).
Alcohol consumption
•  Alcohol consumption in excess of recommended levels was recorded for 17% of those with 
chronic infection. 
•  This was higher in males and in younger people.
Body mass index (BMI)
• BMI was available for only 44% of participants. 
•  The findings may not be representative of the whole population as BMI is more likely to be 
recorded for those who are overweight or underweight.
• 37% were categorised as overweight and a further 30% were obese. 
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Diabetes mellitus
• Diabetes was recorded in 8% of database participants.
• The prevalence of diabetes was higher in those who developed chronic infection (9.6%) than in those 
who never developed chronic infection (5.5%).
Outcomes
Liver-related disease was rare in those who never developed chronic infection so the focus of the results is 
those participants who developed chronic infection.
Clinical signs of severe liver disease
•  29% (n=233) of those who were chronically infected had clinical signs of severe liver disease (such 
as cirrhosis, oesophageal varices, portal hypertension and ascites) recorded at the last follow-up, an 
increase from 22% four years ago.
•  The factors associated with having signs of serious liver disease were longer duration of infection, male 
sex, older age, high alcohol intake, and genotype 3 infection.
•  Those with high alcohol consumption had >5 times higher odds of having serious liver disease 
compared to those without.
•  Participants infected through blood transfusion or treatment for renal disease were more likely to have 
signs of serious liver disease compared to anti-D participants.
Cirrhosis
•  22% (n=181) of those who ever developed chronic infection had developed cirrhosis by latest follow-up. 
This is an increase from 17% four years ago.
• Cirrhosis developed at an average age of 55 years and average duration of infection of 26 years.
•  Older age, longer duration of infection, high alcohol intake, and male sex were all independently 
associated with higher prevalence of cirrhosis on multivariate logistic regression analysis.
•  Participants infected through blood transfusion or treatment for renal disease were more likely to have 
developed cirrhosis compared to those infected through anti-D.
Hepatocellular carcinoma (HCC)
•  HCC had developed in 44 (5%) of those who ever had chronic infection, at an average duration of 
infection of 30 years and an average age of 63 years. This was an increase of 12 cases since four years 
ago.
•  Current chronic infection rather than past chronic infection, male sex, and genotype 3 rather than 
genotype 1 were independently associated with HCC on multivariate logistic regression analysis.
Deaths
• By the end of 2013, 260 participants had died. This is an increase of 48 deaths in the past four years.
•  Among participants who ever developed chronic infection, 23% had died, compared to 8% among 
those who never became chronically infected.
•  Death from liver disease occurred in 73 participants, 63 of whom had been chronically infected and 8 of 
whom had no RNA results (had died before RNA testing began).
•  The factors associated with liver-related mortality on multivariate regression analysis were high alcohol 
intake, male sex, and current chronic infection compared with past chronic infection.
•  Those infected through blood transfusion or clotting factors were more likely to have died from liver-
related causes than the anti-D participants. 
Anti-viral treatment
•  48% (n=390) of chronically infected participants had received at least one course of anti-viral treatment. 
This is an increase from 42% four years ago.
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•  Those who were more likely to have been treated were those who were younger, those infected in the 
1991-1994 anti-D outbreak or through blood transfusion or clotting factors, those with higher fibrosis 
scores and participants with genotype 2 or 3 infections.
•  A sustained virological response (SVR) was more likely to be achieved in younger participants, those 
with genotypes 2 or 3, those who were not cirrhotic prior to treatment and those who did not have high 
levels of alcohol intake.
•  SVR rates for treatment naïve participants who received the standard of care course of pegylated 
interferon (Peg-IFN) and ribavirin (RBV) was 75% for genotypes 2 and 3 and 59% for genotype 1.
•  Thirty seven genotype 1 participants were treated with either telaprevir or boceprevir, in combination 
with Peg-IFN and RBV, by the end of 2013. Treatment response was available for 21 of these, of whom 
17 (81%) achieved an SVR. All those who received at least 24 weeks of treatment (n=15) achieved an 
SVR.
Liver transplants
•  Twenty two database participants had received a liver transplant. The average age at transplant was 54 
years and the average duration of infection was 29 years.
•  All those tested post-transplant were RNA positive.
•  Eleven of the liver transplant recipients had died by the end of 2013. The average time between 
transplant and death for these patients was 29 months.
Focus on three individual patient groups
Detailed descriptions of the three patient groups are provided in Chapter 5.
Summary tables
Please see summary tables 1-12 and figure 1 for further details of main outcomes and infection status, by 
individual patient groups.
Conclusion
This report shows the current or last known health status of 1,320 people infected with HCV through the 
administration of blood or blood products in Ireland. More than half the database population are now in 
their fourth decade since they acquired HCV infection. It is clear that those who did not develop chronic 
HCV infection do not show signs of liver-related disease. Among those who developed chronic infection, 
the majority have not been shown to have signs of liver-related disease. However, a significant number 
have developed serious liver disease such as cirrhosis and liver cancer, some of whom have died. There 
has also been a clear progression in the prevalence of adverse health outcomes overall since the last 
round of data collection four years ago. Of the total database population, 390 people were alive and still 
HCV infected at the end of the current data collection period.
The rapidly shifting therapeutic landscape for HCV infection, with the arrival of new highly effective drug 
regimens, of shorter duration and fewer side effects, offers a more optimistic future for those who still 
have chronic infection. 
The participation rate in the database project is high at 77%. The ongoing support of participants, support 
groups and health professionals is essential to the success of this work. Eligible people who are not yet 
participants in the database may join at any time by contacting their hepatology unit. The database 
project team invites participants, health professionals and researchers to contact us with suggestions for 
further development or improvement of the database, and requests for information from the database.
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liv
er
 d
is
ea
se
99
12
.2
94
22
.0
74
23
.7
44
16
.9
20
17
.2
4
1.
1
C
ir
rh
o
si
s
79
9.
7
77
18
.0
59
18
.9
34
13
.0
18
15
.5
1
0.
3
Li
ve
r 
tu
m
o
ur
s 
o
r 
H
C
C
7
0.
9
7
1.
6
7
2.
2
2
0.
8
0
0.
0
0
0
H
ig
h 
fib
ro
si
s 
sc
o
re
 o
n 
b
io
p
sy
90
11
.1
86
20
.1
63
20
.2
42
16
.1
23
19
.8
3
0.
8
D
ec
ea
se
d
81
10
.0
55
12
.9
51
16
.4
 
 
4
3.
5
25
6.
7
D
ie
d
 f
ro
m
 li
ve
r 
d
is
ea
se
†
20
2.
5
18
4.
3
18
5.
8
 
 
0
0
1
0.
3
* 
  T
he
re
 w
er
e 
no
 R
N
A
 r
es
ul
ts
 in
 t
he
 c
ha
rt
s 
o
f 
10
 p
ar
ti
ci
p
an
ts
. T
he
se
 a
re
 in
cl
ud
ed
 u
nd
er
 a
ll,
 b
ut
 n
o
t 
un
d
er
 e
ve
r 
o
r 
ne
ve
r 
ch
ro
ni
ca
lly
 in
fe
ct
ed
. 
 
 Th
is
 t
ab
le
 in
cl
ud
es
 p
ar
ti
ci
p
an
ts
 in
fe
ct
ed
 in
 n
o
n-
an
ti
-D
 o
ut
b
re
ak
 y
ea
rs
 (n
=
50
) a
nd
 t
ho
se
 in
fe
ct
ed
 in
 o
ut
b
re
ak
 y
ea
rs
 (1
99
1-
19
94
), 
b
ut
 w
ho
 d
id
 n
o
t 
ha
ve
 t
he
 r
el
ev
an
t 
o
ut
b
re
ak
 g
en
o
ty
p
e 
(n
=
6)
. 
† 
  D
en
o
m
in
at
o
r 
fo
r 
th
is
 is
 a
ll 
p
ar
ti
ci
p
an
ts
 m
in
us
 n
in
e 
p
ar
ti
ci
p
an
ts
 w
ho
 h
av
e 
d
ie
d
 b
ut
 w
ho
se
 c
au
se
 o
f 
d
ea
th
 w
as
 n
o
t 
av
ai
la
b
le
 (n
=
80
2)
Ta
b
le
 4
. 
C
ur
re
nt
 R
N
A
 s
ta
tu
s 
fo
r 
al
l a
nt
i-D
 p
ar
ti
ci
p
an
ts
R
N
A
 s
ta
tu
s 
b
as
ed
 o
n 
m
o
st
 r
ec
en
t 
R
N
A
 r
es
ul
ts
A
ll
C
ur
re
nt
ly
 a
liv
e
D
ec
ea
se
d
  
  
  
  
 N
um
 
  
 %
  
  
  
  
 N
um
 
  
 %
  
  
  
  
  
N
um
 
  
 %
C
hr
o
ni
ca
lly
 in
fe
ct
ed
, n
ev
er
 t
re
at
ed
23
0
28
.4
19
8
27
.1
32
39
.5
C
hr
o
ni
ca
lly
 in
fe
ct
ed
, t
re
at
ed
, 
no
 S
V
R
82
10
.1
63
8.
6
19
23
.5
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 t
re
at
ed
, S
V
R
92
11
.3
90
12
.3
2
2.
5
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 t
re
at
ed
, a
w
ai
ti
ng
 r
es
p
o
ns
e,
 b
ut
 la
st
 
R
N
A
 t
es
t 
ne
g
at
iv
e
9
1.
1
9
1.
2
0
0
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 t
re
at
ed
, n
o
 S
V
R
, b
ut
 s
ub
se
q
ue
nt
ly
 
te
st
ed
 R
N
A
 n
eg
at
iv
e
1
0.
1
0
0
1
1.
2
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 s
p
o
nt
an
eo
us
 r
es
o
lu
ti
o
n
14
1.
7
13
1.
8
1
1.
2
N
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
, c
o
nf
ir
m
ed
 p
o
si
ti
ve
15
2
18
.7
13
7
18
.8
15
18
.5
N
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
, n
o
t 
co
nf
ir
m
ed
 p
o
si
ti
ve
22
1
27
.3
21
1
28
.9
10
12
.3
N
o
 R
N
A
 r
es
ul
ts
 in
 c
ha
rt
, c
o
nf
ir
m
ed
 p
o
si
ti
ve
1
0.
1
1
0.
1
0
0
N
o
 R
N
A
 r
es
ul
ts
 in
 c
ha
rt
, n
o
t 
co
nf
ir
m
ed
 p
o
si
ti
ve
9
1.
2
8
1.
1
1
1.
2
To
ta
l
8
1
1
1
0
0
7
3
0
1
0
0
8
1
1
0
0
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Tab
le 5
. Sum
m
ary o
f m
ain o
utco
m
es b
y hep
atitis C
 R
N
A
 status fo
r anti-D
 p
articip
ants infected
 b
etw
een 1
9
7
7
 and
 1
9
7
9
 O
utco
m
es
A
ll* (n=
6
8
2
)
E
ver chro
nically 
infected
 (n=
3
7
4
)
C
urrently chro
nically 
infected
 (n=
2
9
8
)
A
live and
 currently 
chro
nically infected
 
(n=
2
4
7
)
C
hro
nically infected
 in 
the p
ast (n=
7
6
)
N
ever chro
nically 
infected
 (n=
3
0
2
)
A
nti-D
 1
9
7
7
-1
9
7
9
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
Sig
ns o
f liver d
isease
92
13.5
87
23.3
70
23.5
40
16.2
17
22.4
4
1.3
C
irrho
sis
74
10.9
72
19.3
56
18.8
31
12.6
16
21.1
1
0.3
Liver tum
o
urs o
r H
C
C
7
1.0
7
1.9
7
2.4
2
0.8
0
0
0
0
H
ig
h fib
ro
sis sco
re o
n b
io
p
sy
87
12.8
83
22.2
62
20.8
41
16.6
21
27.6
3
1.0
D
eceased
79
11.6
53
14.2
51
17.1
 
 
2
2.6
25
8.3
D
ied
 fro
m
 liver d
isease †
20
3.0
18
4.9
18
6.1
 
 
0
0
1
0.3
*   There w
ere no
 R
N
A
 results in the charts o
f 6 p
articip
ants. These are includ
ed
 und
er all, b
ut no
t und
er ever o
r never chro
nically infected
 
†  D
eno
m
inato
r fo
r this is all p
articip
ants m
inus eig
ht p
articip
ants w
ho
 have d
ied
 b
ut w
ho
se cause o
f d
eath w
as no
t availab
le (n=
674)
Tab
le 6
. C
urrent R
N
A
 status fo
r anti-D
 p
articip
ants infected
 b
etw
een 1
9
7
7
 and
 1
9
7
9
R
N
A
 status b
ased
 o
n m
o
st recent R
N
A
 results
A
ll
C
urrently alive
D
eceased
          N
um
 
     %
          N
um
 
    %
           N
um
 
    %
C
hro
nically infected
, never treated
222
32.6
190
31.5
32
40.5
C
hro
nically infected
, treated
, no
 SV
R
76
11.1
57
9.5
19
24.1
P
ast chro
nic infectio
n, treated
, SV
R
55
8.1
54
9.0
1
1.3
P
ast chro
nic infectio
n, treated
, aw
aiting
 
resp
o
nse, b
ut last R
N
A
 test neg
ative
9
1.3
9
1.5
0
0
P
ast chro
nic infectio
n, sp
o
ntaneo
us reso
lutio
n
12
1.8
11
1.8
1
1.3
N
ever chro
nically infected
, co
nfirm
ed
 p
o
sitive
141
20.7
126
20.9
15
19.0
N
ever chro
nically infected
, no
t co
nfirm
ed
 
p
o
sitive
161
23.6
151
25.0
10
12.7
N
o
 R
N
A
 results in chart
6
0.9
5
0.8
1
1.3
To
tal 
6
8
2
1
0
0
6
0
3
1
0
0
7
9
1
0
0
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Ta
b
le
 7
. 
Su
m
m
ar
y 
o
f 
m
ai
n 
o
ut
co
m
es
 b
y 
he
p
at
it
is
 C
 R
N
A
 s
ta
tu
s 
fo
r 
an
ti
-D
 p
ar
ti
ci
p
an
ts
 in
fe
ct
ed
 b
et
w
ee
n 
1
9
9
1
 a
nd
 1
9
9
4
 O
ut
co
m
es
A
ll*
 (
n=
7
3
)
E
ve
r 
ch
ro
ni
ca
lly
 in
fe
ct
ed
 (
n=
3
7
)
N
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
 (
n=
3
2
)
A
nt
i-D
 1
9
9
1
-1
9
9
4
N
um
%
N
um
%
N
um
%
Si
g
ns
 o
f 
liv
er
 d
is
ea
se
5
6.
9
5
13
.5
0
0
C
ir
rh
o
si
s
3
4.
1
3
8.
1
0
0
Li
ve
r 
tu
m
o
ur
s 
o
r 
H
C
C
0
0
0
0
0
0
H
ig
h 
fib
ro
si
s 
sc
o
re
 o
n 
b
io
p
sy
2
2.
7
2
5.
4
0
0
D
ec
ea
se
d
1
1.
4
1
2.
7
0
0
D
ie
d
 f
ro
m
 li
ve
r 
d
is
ea
se
†
0
0
0
0
0
0
* 
  T
he
re
 w
er
e 
no
 R
N
A
 r
es
ul
ts
 in
 t
he
 c
ha
rt
s 
o
f 
4 
p
ar
ti
ci
p
an
ts
. T
he
se
 a
re
 in
cl
ud
ed
 u
nd
er
 a
ll,
 b
ut
 n
o
t 
un
d
er
 e
ve
r 
o
r 
ne
ve
r 
ch
ro
ni
ca
lly
 in
fe
ct
ed
† 
 D
en
o
m
in
at
o
r 
fo
r 
th
is
 is
 a
ll 
p
ar
ti
ci
p
an
ts
 m
in
us
 o
ne
 p
ar
ti
ci
p
an
t 
w
ho
 h
as
 d
ie
d
 b
ut
 w
ho
se
 c
au
se
 o
f 
d
ea
th
 w
as
 n
o
t 
av
ai
la
b
le
 (n
=
72
)
 N
o
te
: 6
 p
ar
ti
ci
p
an
ts
 w
ho
 w
er
e 
in
fe
ct
ed
 d
ur
in
g
 t
hi
s 
an
ti
-D
 o
ut
b
re
ak
 p
er
io
d
, b
ut
 w
ho
 d
id
 n
o
t 
ha
ve
 t
hi
s 
o
ut
b
re
ak
 g
en
o
ty
p
e 
ar
e 
ex
cl
ud
ed
 f
ro
m
 t
hi
s 
ta
b
le
. 
Fo
ur
 p
ar
ti
ci
p
an
ts
 r
em
ai
n 
cu
rr
en
tl
y 
ch
ro
ni
ca
lly
 in
fe
ct
ed
 a
nd
 a
liv
e 
an
d
 3
3 
w
er
e 
ch
ro
ni
ca
lly
 in
fe
ct
ed
 in
 t
he
 p
as
t.
 L
iv
er
-r
el
at
ed
 o
ut
co
m
es
 a
re
 n
o
t 
sh
o
w
n 
fo
r 
th
es
e 
p
at
ie
nt
s 
to
 e
ns
ur
e 
th
at
 t
he
y 
ar
e 
no
t 
id
en
ti
fia
b
le
.
Ta
b
le
 8
. 
C
ur
re
nt
 R
N
A
 s
ta
tu
s 
fo
r 
an
ti
-D
 p
ar
ti
ci
p
an
ts
 in
fe
ct
ed
 b
et
w
ee
n 
1
9
9
1
 a
nd
 1
9
9
4
R
N
A
 s
ta
tu
s 
b
as
ed
 o
n 
m
o
st
 r
ec
en
t 
R
N
A
 r
es
ul
ts
A
ll
C
ur
re
nt
ly
 a
liv
e
  
  
  
  
  
  
  
  
N
um
 
  
  
  
  
  
  
  
  
 %
  
  
  
  
  
  
  
  
N
um
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 %
C
hr
o
ni
ca
lly
 in
fe
ct
ed
, 
ne
ve
r 
tr
ea
te
d
1
1.
4
1
1.
4
C
hr
o
ni
ca
lly
 in
fe
ct
ed
, t
re
at
ed
, 
no
 S
V
R
3
4.
1
3
4.
2
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 t
re
at
ed
, S
V
R
31
42
.5
30
41
.7
P
as
t 
ch
ro
ni
c 
in
fe
ct
io
n,
 s
p
o
nt
an
eo
us
 r
es
o
lu
ti
o
n
2
2.
7
2
2.
8
N
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
, c
o
nf
ir
m
ed
 p
o
si
ti
ve
5
6.
9
5
6.
9
N
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
, n
o
t 
co
nf
ir
m
ed
 p
o
si
ti
ve
27
37
.0
27
37
.5
N
o
 R
N
A
 r
es
ul
ts
 in
 c
ha
rt
4
5.
5
4
5.
6
To
ta
l 
7
3
1
0
0
7
2
1
0
0
N
o
te
: 6
 p
ar
ti
ci
p
an
ts
 w
ho
 w
er
e 
in
fe
ct
ed
 d
ur
in
g
 t
hi
s 
an
ti
-D
 o
ut
b
re
ak
 p
er
io
d
, b
ut
 w
ho
 d
id
 n
o
t 
ha
ve
 t
hi
s 
o
ut
b
re
ak
 g
en
o
ty
p
e 
ar
e 
ex
cl
ud
ed
 f
ro
m
 t
hi
s 
ta
b
le
. 
O
ne
 p
ar
ti
ci
p
an
t 
w
as
 d
ec
ea
se
d
. F
ur
th
er
 d
et
ai
ls
 a
re
 n
o
t 
sh
o
w
n 
fo
r 
th
is
 p
at
ie
nt
 t
o
 e
ns
ur
e 
th
at
 t
he
y 
ar
e 
no
t 
id
en
ti
fia
b
le
.
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Tab
le 9
. Sum
m
ary o
f m
ain o
utco
m
es b
y hep
atitis C
 R
N
A
 status fo
r b
lo
o
d
 transfusio
n/renal p
articip
ants
 O
utco
m
es
A
ll* (n=
3
3
7
)
E
ver chro
nically 
infected
 (n=
2
7
4
)
C
urrently chro
nically 
infected
 (n=
1
8
6
)
A
live and
 currently 
chro
nically infected
 
(n=
9
9
)
C
hro
nically infected
 
in the p
ast (n=
8
8
)
N
ever chro
nically 
infected
 (n=
6
1
)
B
lo
o
d
 transfusio
n/renal
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
Sig
ns o
f liver d
isease
102
30.3
99
36.1
79
42.5
36
36.4
20
22.7
2
3.3
C
irrho
sis
84
24.9
82
29.9
64
34.4
27
27.3
18
20.5
1
1.6
Liver tum
o
urs o
r H
C
C
27
8.0
27
9.9
26
14.0
5
5.1
1
1.1
0
0
H
ig
h fib
ro
sis sco
re o
n 
b
io
p
sy
83
24.6
80
29.2
54
29.0
24
24.2
26
29.6
2
3.3
D
eceased
104
30.9
93
33.9
87
46.8
 
 
6
6.8
9
14.8
D
ied
 fro
m
 liver d
isease †
32
9.8
31
11.6
28
15.6
 
 
3
3.4
1
1.7
* T here w
ere no
 R
N
A
 results in the charts o
f 2 p
articip
ants (b
o
th d
eceased
). These are includ
ed
 und
er all, b
ut no
t und
er ever o
r never chro
nically infected
 
†  D
eno
m
inato
r fo
r this is all p
articip
ants m
inus nine p
articip
ants w
ho
 have d
ied
 b
ut w
ho
se cause o
f d
eath w
as no
t availab
le (n=
328)
Tab
le 1
0
. C
urrent R
N
A
 status fo
r b
lo
o
d
 transfusio
n/renal p
articip
ants
R
N
A
 status b
ased
 o
n m
o
st recent R
N
A
 
results
A
ll
C
urrently alive
D
eceased
          N
um
 
     %
          N
um
 
     %
          N
um
 
   %
C
hro
nically infected
, never treated
122
36.2
63
27.0
59
56.7
C
hro
nically infected
, treated
, no
 SV
R
64
19.0
36
15.5
28
26.9
P
ast chro
nic infectio
n, treated
, SV
R
72
21.4
68
29.2
4
3.8
P
ast chro
nic infectio
n, treated
, aw
aiting
 
resp
o
nse, b
ut last R
N
A
 test neg
ative
7
2.1
7
3.0
0
0
P
ast chro
nic infectio
n, treated
, no
 SV
R
, b
ut 
sub
seq
uently tested
 R
N
A
 neg
ative
1
0.3
0
0
1
1.0
P
ast chro
nic infectio
n, sp
o
ntaneo
us reso
lutio
n
8
2.4
7
3.0
1
1.0
N
ever chro
nically infected
, co
nfirm
ed
 p
o
sitive
28
8.3
22
9.4
6
5.8
N
ever chro
nically infected
, no
t co
nfirm
ed
 
p
o
sitive
33
9.8
30
12.9
3
2.9
N
o
 R
N
A
 results in chart
2
0.6
0
0
2
1.9
To
tal
3
3
7
1
0
0
2
3
3
1
0
0
1
0
4
1
0
0
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Ta
b
le
 1
1
. 
Su
m
m
ar
y 
o
f 
m
ai
n 
o
ut
co
m
es
 b
y 
he
p
at
it
is
 C
 R
N
A
 s
ta
tu
s 
fo
r 
b
lo
o
d
 c
lo
tt
in
g
 f
ac
to
r 
p
ar
ti
ci
p
an
ts
 O
ut
co
m
es
A
ll 
(n
=
1
6
5
)
E
ve
r 
ch
ro
ni
ca
lly
 
in
fe
ct
ed
 (
n=
1
0
7
)
C
ur
re
nt
ly
 
ch
ro
ni
ca
lly
 
in
fe
ct
ed
 (
n=
6
1
)
A
liv
e 
an
d
 
cu
rr
en
tl
y 
ch
ro
ni
ca
lly
 
in
fe
ct
ed
 (
n=
2
8
)
C
hr
o
ni
ca
lly
 
in
fe
ct
ed
 in
 t
he
 
p
as
t 
(n
=
4
6
)
N
ev
er
 c
hr
o
ni
ca
lly
 
in
fe
ct
ed
 (
n=
2
1
)
N
o
 R
N
A
 r
es
ul
ts
 
(n
=
3
7
)
B
lo
o
d
 c
lo
tt
in
g
 f
ac
to
rs
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
N
um
%
Si
g
ns
 o
f 
liv
er
 d
is
ea
se
44
26
.7
39
36
.5
32
52
.5
11
39
.3
7
15
.2
0
0
5
13
.5
C
ir
rh
o
si
s
24
14
.6
21
19
.6
20
32
.8
4
14
.3
1
2.
2
0
0
3
8.
1
Li
ve
r 
tu
m
o
ur
s 
o
r 
H
C
C
12
7.
3
10
9.
4
10
16
.4
2
7.
1
0
0
0
0
2
5.
4
H
ig
h 
fib
ro
si
s 
sc
o
re
 o
n 
b
io
p
sy
†
12
7.
3
12
11
.2
8
13
.1
2
7.
1
4
8.
7
0
0
0
0
D
ec
ea
se
d
74
44
.9
36
33
.6
33
54
.1
 
 
3
6.
5
1
4.
8
37
10
0
D
ie
d
 f
ro
m
 li
ve
r 
d
is
ea
se
*
20
12
.5
13
12
.4
13
21
.7
 
 
0
0
0
0
7
20
.6
* 
 D
en
o
m
in
at
o
r 
fo
r 
th
is
 is
 a
ll 
p
ar
ti
ci
p
an
ts
 m
in
us
 fi
ve
 p
ar
ti
ci
p
an
ts
 w
ho
 h
av
e 
d
ie
d
 b
ut
 w
ho
se
 c
au
se
 o
f 
d
ea
th
 w
as
 n
o
t 
av
ai
la
b
le
 (n
=
16
0)
†L
iv
er
 b
io
p
sy
 o
n 
o
nl
y 
42
%
 o
f 
ev
er
 c
hr
o
ni
ca
lly
 in
fe
ct
ed
Ta
b
le
 1
2
. 
C
ur
re
nt
 R
N
A
 s
ta
tu
s 
fo
r 
b
lo
o
d
 c
lo
tt
in
g
 f
ac
to
r 
p
ar
ti
ci
p
an
ts
R
N
A
 s
ta
tu
s 
b
as
ed
 o
n 
m
o
st
 r
ec
en
t 
R
N
A
 r
es
ul
ts
A
ll
C
ur
re
nt
ly
 a
liv
e
D
ec
ea
se
d
  
  
  
 N
um
  
  
  
  
  
  
  
  
 %
  
  
  
N
um
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Figure 1. Summary of database participation, RNA status, and disease progression by RNA status, for all 
participants and by source of infection  
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Hepatitis C infection is a major cause of chronic liver disease and death throughout the world.1 
Approximately 3% of the world’s population is infected with hepatitis C virus (HCV).2 Hepatitis C infection 
is caused by an RNA virus that was first identified in 1989.3 Six distinct but related genotypes and multiple 
subtypes have been identified. In Western Europe genotypes 1a and 1b are most common, followed by 
genotypes 2 and 3.4
HCV is transmitted by blood and now occurs primarily through injecting drug use, and less frequently 
through sex with an infected partner, occupational exposure, and mother to infant transmission. In 
some cases no risk factors can be identified.4,5 Transfusion-related HCV infection is rare now since the 
introduction of routine screening of blood for HCV antibodies in the early 1990s.
Acute HCV infection, in general, is relatively mild with only 20%-30% of infected people developing 
symptoms or clinically evident acute infection.2 In most people who become infected with HCV, viremia 
persists, that is, virus continues to be present in the circulation. Chronic HCV infection is marked by 
persistence of HCV RNA for at least 6 months after onset of infection. Spontaneous resolution after 6 or 
12 months of infection is unusual.3 Between 55% and 85% of those infected develop chronic infection6, 
the lower end of the range being accounted for mainly by women, particularly young women.7,8 
Spontaneous resolution of chronic hepatitis C is relatively rare, but can occur.9
Chronically infected people are at risk of progressive liver disease characterised by hepatocellular 
inflammation, hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC).6 These complications 
develop only in a proportion of patients and only after many years or decades of infection.3 It has been 
estimated that up to 20% of chronically infected individuals will develop cirrhosis of the liver over a 20 to 
25 year period. Approximately 3% to 4% of patients with cirrhosis will develop HCC per year.10 Factors 
that have been shown to be associated with progression of liver fibrosis include older age at infection, 
male sex, genetic factors, metabolic factors (steatosis, diabetes and obesity), co-infection with human 
immunodeficiency virus (HIV) or hepatitis B, duration of infection, and alcohol intake.1,4,6,10
Chronic HCV infection has been associated with several extrahepatic manifestations including essential 
mixed cryoglobulinemia, B-cell non-Hodgkin lymphoma, glomerulonephritis, seronegative arthritis, 
keratoconjunctivitis sicca and sialadenitis, lichen planus, neuropathies and neurological conditions 
including cognitive disorders and porphyria cutanea tarda.3
Recently, there have been major advances in hepatitis C treatments. Until 2011, the standard of care was 
a combination of pegylated interferon (PegIFN) and ribavirin (RBV) for 24 to 48 weeks, depending on the 
genotype. This resulted in a successful response to treatment (SVR - sustained virological response) in 
more than 75% of patients with genotypes 2 and 3 HCV infection, and 40-50% of those with genotype 
1.11,12 
In 2011, telaprevir and boceprevir were licensed for HCV genotype 1 infection and came into use in 
Ireland in 2012. These two protease inhibitor drugs are first generation direct acting antivirals (DAAs) and 
are used in combination with PegIFN and RBV. This combination has been shown to achieve higher SVR 
rates than the previous regimen, but with additional side effects.13 Three new HCV DAAs were licensed 
in the EU in 2014, for use as part of combination therapies for HCV infection: sofosbuvir, simeprevir 
and daclatasvir. Each of these can be used in combination with PegIFN and RBV, yielding SVR rates of 
60-100%. These new DAAs, and others which have since been approved, are now also used in interferon-
free combinations, initially as part of early access programmes in patients with advanced liver disease, and 
have been shown to achieve very high SVR rates and to be well tolerated.13
Chapter 1. Hepatitis C virus infection
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Figure 2. Summary of natural history of hepatitis C infection
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Chapter 2. National Hepatitis C Database
2.1 Background to the database
The National Hepatitis C Database was set up in 2004 by the HSE-Health Protection Surveillance Centre 
(HPSC) in association with eight specialist hepatology units to collect data on people who were identified 
as being infected with HCV through the receipt of contaminated blood and blood products in Ireland. 
These include women infected through anti-D immunoglobulin, recipients of blood transfusions, people 
with haemophilia and other blood clotting disorders and people who received treatment for renal 
disease.14 Specialist hepatology services were set up in eight designated hospitals to provide services for 
this group, which numbers approximately 1,700 people. Those infected are also entitled to a range of 
additional hospital and primary care services under the Health (Amendment) Act, 1996 (HAA). 
Approval for this project was obtained from the ethics committees of all eight hospitals and from the 
Office of the Data Protection Commissioner. The development and management of the database project 
is overseen by a Steering Committee (appendix A). A Scientific and Technical Group supports and advises 
HPSC on the scientific and technical development of the database (appendix B).
2.2 The objectives of the database are: 
1. To follow the natural history of infection in people infected with hepatitis C through blood and 
blood products
2. To evaluate the impact of various host factors on the progression of the disease
3. To evaluate the outcomes of treatment
4. To monitor the uptake of services
5. To provide information for the planning and evaluation of health services
6. To serve as a resource for future research into hepatitis C
2.3 Data collection and reporting
Baseline data were collected in 2005 and 2006 and included all relevant data from the date of diagnosis 
on all consented participants and those who had died. A baseline report15 describing these data was 
published in October 2007. Three follow-up reports have been published since baseline data collection, in 
2009, 2010 and 2012.16,17,18 This is the fourth follow-up report and includes information on all participants 
up to the end of 2013. All reports and patient newsletters are available through the hepatology units, 
patient support groups, hepatitis C liaison officers and on the database website 
(www.hcvdatabase.ie).
2.4 Database population
Any person (alive or dead) who contracted HCV infection through the administration of blood or blood 
products within the state is eligible to be included in the database. These include women infected through 
anti-D immunoglobulin, recipients of blood transfusion, people with haemophilia and other blood clotting 
disorders and people who received treatment for renal disease. Eligible patients were identified by the 
eight specialist hepatology units.15
For the purpose of this database, hepatitis C infection is defined as the detection of hepatitis C specific 
antibodies or the detection of hepatitis C nucleic acid. This includes all those who tested ELISA (enzyme 
linked immunosorbent assay)/EIA (enzyme immunoassay) positive or weak positive, recombinant 
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immunoblot assay (RIBA)/INNO-LIA positive or indeterminate, or hepatitis C polymerase chain reaction 
(PCR)/RNA positive. 
People with positive or weak positive ELISA/EIA tests or indeterminate RIBA/INNO-LIA tests were 
included in the database as many patients were tested many years after the time of suspected infection, 
having had documented exposure to HCV, and some of these may have cleared the virus and since 
sero-reverted. HCV antibody levels have been demonstrated to drop below detection limits in some 
patients.19,20,21
Information is collected only on eligible people who consent to participate in the database and on eligible 
participants who have died. Relatives of deceased people are entitled to refuse participation, and no data 
are collected on those who refused to participate in the database when they were alive. 
2.5 Source of data
Information is gathered from the participants’ medical records (hospital charts) in the eight hepatology 
units. No direct contact is made with any participant. No names or addresses are recorded in the 
database. 
2.6 Data security
The database was built using MS SQL server 2000. It is physically located in a secure computer room in 
HPSC with access strictly limited to key technical support staff. Access to the database is secured by a 
combination of network, SQL server and MS Access security permissions. All paper forms are stored in a 
locked cabinet in HPSC. 
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Chapter 3. Methods: Data period 2010-2013
3.1 Data Collection
The fourth round of follow-up data collection began in January 2014 and captured data on patients up 
to 31st December 2013.  Data were extracted from the participants’ medical notes by a HPSC research 
nurse. Information collected included clinical, demographic and lifestyle data which had been added to 
the participants’ medical records between the date of last data collection (up to the end of 2009) and the 
date of follow-up data collection (up to 31st December 2013). Data were entered into the database by a 
surveillance assistant. Double entry was used to maximise accuracy. In order to improve the information 
held on participants, additional data fields were included in the latest follow-up data collection form 
(appendix C).
3.2 Recruitment of new participants 
Recruitment of new participants to the database is ongoing and new participants are welcome to join 
at any time. These include people who did not consent to database participation when first invited to 
do so in 2004, and those who have been newly identified as eligible since 2004. Patients are given the 
opportunity to consent at their hospital appointments where they are given further information about 
the database by staff. This has proven to be a successful method of encouraging patients who have not 
yet consented to consider participating in the database. Those who refused to consent at any time are 
not asked again. The patient support groups also encourage their members to participate through their 
newsletters and meetings.
There is a small number of people living abroad (approximately 25; personal communication, Michelle Tait 
HSE), who meet the eligibility criteria for the database but who do not attend a clinical service in Ireland. 
They are not currently included in the database due to the difficulties that would arise in terms of data 
collection, data quality, confidentiality and consent.
3.3 Assumptions
Various assumptions were made where data were missing. These related mainly to the year of infection. 
These assumptions were:
• Anti-D: If the person had received anti-D on multiple occasions, and one of these was the year of 
an outbreak period, i.e. 1977-1979 or 1991-1994, this year was taken as the year of infection. If 
none of the years fell into either of the outbreak periods, the earliest year that anti-D had been 
administered was used as the year of infection.
• Blood transfusion/treatment for renal disease: If the person had received multiple blood transfusions 
and none of them had been identified as being infectious, the earliest transfusion year was taken 
as the year of infection. Where the person had also been on dialysis for extended periods of time, 
the year of starting dialysis or of first blood transfusion, whichever was the earlier, was used as an 
estimate of the year of infection.
• Clotting factors: For people with haemophilia and other blood clotting disorders, if the year of 
infection was not available, the year that the patient first received clotting factors was used as 
a proxy for the year of infection. Where the year of infection and the year when first factor was 
administered were missing, then the year of diagnosis of haemophilia was used as the year of 
infection. 
• Where precise day or month were missing from dates (e.g. date of infection), the year of infection 
was converted to 02/07/YYYY, where YYYY was the year of infection and 02/07 was the midpoint of 
the year. All calculated ages were truncated and all durations were rounded based on the outcome 
of the calculation. 
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3.4 Assigning dates of diagnosis of cirrhosis and hepatocellular carcinoma 
(HCC)/liver cancer
Variables were created to indicate if participants had cirrhosis or HCC on biopsy, ultrasound, CT, MRI 
or fibroscans, or mentioned elsewhere in their medical charts or death certificates. The earliest date 
mentioned in relation to a diagnosis of cirrhosis or HCC was used as a date of diagnosis. In some cases, 
particularly where cirrhosis or HCC were recorded in a patient’s medical records when baseline data 
collection was done, the only information available was a diagnosis recorded when the patient first or 
last attended the hepatology unit and these dates may not accurately reflect when a patient developed 
cirrhosis or HCC.
3.5 Estimating duration of hepatitis C ribonucleic acid (RNA) positivity
All RNA results were recorded for each participant. A variable was created to record the duration of RNA 
positivity in years for all participants who ever tested RNA positive. The following rules were used:
• If a participant remained RNA positive when last tested and was still alive, the duration of RNA 
positivity was calculated as their date of last hepatology visit/last test result minus their date of 
infection. If they were deceased, their date of death minus their date of infection was used.
• For participants who had tested RNA positive and cleared the virus, the duration of RNA positivity 
was calculated as the midpoint between the first negative and last positive result minus their date 
of infection.
3.6 Interpretation and presentation of HCV test results
3.6.1 HCV tests and their meaning
RNA tests are used to test for circulating virus. Positive results indicate current infection. Antibody tests 
indicate if a person has ever been HCV infected, even if they no longer have circulating virus. In general, 
ELISA/EIA tests are used as screening tests for HCV antibodies, and line-immunoassay tests (e.g. RIBA/
INNO-LIA) are used to confirm positive antibody results. The combination of a positive HCV antibody 
result and a negative RNA result indicates past infection.
3.6.2 Chronic HCV infection
As the vast majority of participants were diagnosed some years after infection, “ever testing RNA 
positive” can be taken to indicate that the person had developed chronic long-term infection. Throughout 
this report, we treat participants who ever tested RNA positive as having been chronically infected 
with HCV and these participants are the primary focus when looking at clinical outcomes and disease 
progression to date. 
3.6.3 Spontaneous viral clearance
We have no way of knowing the timing of viral clearance for participants who cleared the virus 
spontaneously prior to HCV testing (and thus had no positive RNA results). However, studies have found 
that spontaneous viral clearance usually occurs within a year of infection, so we assumed that these 
participants experienced acute infection only and were never chronically infected.22,23
3.6.4 Categorisation by RNA status
In order to facilitate the comparison of participants who developed chronic infection and those who 
cleared the virus spontaneously after acute infection with HCV and never developed chronic infection, 
most data are presented separately for participants who ever tested RNA positive and those who had 
RNA tests done but had no positive RNA results. The small number of participants who had no RNA 
results in their charts were omitted from most of the results presented by RNA status as they could not 
be classified as either “ever” or “never” testing RNA positive. Results for the ever RNA positive group are 
also presented separately for those who remain chronically infected (currently chronically infected) and 
those who were chronically infected in the past and have since cleared the virus (chronically infected in 
past), mostly as a result of anti-viral treatment.
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3.7 Categorisation of alcohol consumption
At the time of setting up this database, the low-risk drinking guidelines for the general population in 
Ireland defined an upper limit of 21 units (standard drinks) per week for males and 14 units per week 
for females.24 (Note: Low-risk drinking guidelines have been revised and are now defined as 17 standard 
drinks for men and 11 standard drinks for women, per week.25) Participants consuming above these limits 
(21 for males, 14 for females) and under 40 units per week were classified as having moderately high 
alcohol intake and those consuming over 40 units were classified as having high alcohol intake. Some 
data on the number of units of alcohol consumed per week were available for 94% of those who became 
chronically infected. However, it is unusual for alcohol consumption to have been recorded at every visit, 
and in many cases it was last recorded many years ago. Alcoholic liver disease or alcohol abuse was also 
mentioned in the charts of some participants. This additional information was combined with alcohol 
intake data when looking at the effects of alcohol on disease progression and these participants were 
considered to have had high alcohol intake at some stage (i.e. alcoholic liver disease, alcohol abuse or 
>40 units per week). 
3.8 Coding of death certificates
Death certificates were collected on deceased participants from the General Register Office (GRO). This 
was done by the research nurse, acting on behalf of the hepatology unit. No named data were brought to 
HPSC. The cause of death was coded using the World Health Organization (WHO) ICD-10 coding format. 
Analysis was done on the underlying cause of death as defined by the ICD system. 
The cause of death was further classified using the following broad categories:
	 • Death directly caused by liver-related disease
	 •  Death not directly caused by liver-related disease, but liver-disease or hepatitis C listed as a 
contributing condition on the death certificate
	 • Death was not liver-related
Death was considered to be directly caused by liver-related disease in the following situations:
If hepatocellular carcinoma or end-stage liver disease (varices, ascites, liver failure or hepatic 
encephalopathy) were listed as any of the causes of death in section I of the death certificate
Or if liver disease was not specified as end-stage (e.g. cirrhosis) but the sequence of causes of death on 
the certificate suggested death was due to liver disease, 
Or if liver disease was coded as the underlying and only cause of death.
The classification of all deaths was carried out by a consultant hepatologist and a medical epidemiologist, 
blinded to the hepatitis C immunoblot or RNA status of the patient.
3.9 Long-term medications
Long term medications mentioned in the patient’s chart are recorded in the database and were coded 
using the Anatomical Therapeutic Chemical (ATC) classification system. This is a standardised coding 
system, controlled by the World Health Organization, and is based on the organ or system on which the 
drug acts. 
3.10 Liver biopsies
Different scoring systems were used to stage and grade the hepatitis C liver biopsies in the different 
hepatology units (appendix D):
	 • Knodell system:26 fibrosis scored from 0-4 
	 •  Modified Knodell system,27,28 also known as the Ishak or the modified HAI system: fibrosis scored 
from 0-6 
	 • Scheuer system:29 fibrosis scored from 0-4
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For some of the analyses, the biopsies scored from 0 to 6 were converted to 0 to 4 scores so that all 
scored biopsies could be considered together. The following conversions were used: 0=0, 1=1, 2=1, 3=2, 
4=3, 5=3 and 6=4. 
 
3.11 Fibroscan results
Fibroscan results provide useful indicators of advanced fibrosis and cirrhosis, but are not as accurate at 
distinguishing mild to moderate fibrosis. Results may also vary depending on the success rate of the scan 
and physiological features of the patient, particularly high BMI and abdominal adiposity. We interpreted 
scores of 9.5-14.4 kPa as indicating that the patient may have advanced fibrosis and scores of 14.5 kPa or 
higher as indicating that the patient may have cirrhosis.30 
3.12 Data analysis
Data analysis was done using Microsoft Access 2010, Microsoft Excel 2010 and Stata/SE version 11.2. 
Either Pearson’s chi-square or the Wald test, with corresponding probability value (p-value) and 95% 
confidence intervals, were used to test for differences between odds of a given outcome. Logistic 
regression was used to investigate which patient and virus characteristics were independently associated 
with key liver-related outcomes.  The logistic regression models were mostly used to examine the 
determinants of key liver-related outcomes in participants who were ever chronically HCV infected and 
generally initially included sex, alcohol consumption, age at end of follow-up, duration of infection, 
HCV genotype and BMI. Models were also created with source of infection instead of sex as these two 
variables were too closely linked for the effect of both to be examined in the same model. Cox regression 
was used in survival analyses and survival curves were derived using the Kaplan Meier method. All 
statistical tests were 2-tailed and a p-value of <0.05 was taken as statistically significant. 
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Chapter 4. Main Findings
The summary tables 1-12 at the beginning of this report provide details of RNA status and outcomes by source 
of infection group
4.1 Participation rates and representativeness of the database cohort
The overall participation rate in the database is now 77%, including people who have died, and the consent 
rate is 74% (figure 3). Six people have consented and been added to the database since the last round of data 
collection and one person removed (found to be ineligible), bringing the total number of participants to 1,320. 
Figure 3 details the response rate by source of infection.
Figure 3. Summary of database cohort and participation rates by source of infection and sex
Note: Source of infection = “Other/unknown” includes participants infected through vertical or sexual contact with people with state-
acquired infection. 
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Database participation increased with increasing age up to the mid-60s and declined slightly thereafter. 
This difference was statistically significant and was also evident when deceased patients were excluded 
from the analysis (consenting persons only). There was no significant difference in participation rate for 
females and males: 78% of females (n=1025) and 75% of males (n=295). People infected through blood 
clotting factors (73%) were significantly less likely to be included in the database compared to blood 
transfusion/renal patients (81%).
4.2 Hepatitis C infection status and RNA results
4.2.1 Hepatitis C test results
See Methods section 3.6 regarding interpretation of HCV test results.
Overall, 62% (n=813) of database participants had at least one positive RNA result in their charts and 
a further 15% (n=202) had positive confirmatory tests for HCV antibodies (e.g. RIBA/INNO-LIA) but no 
positive RNA results (figure 4). The remaining 23% (n=305) tested either ELISA/EIA positive or weak 
positive, or RIBA/INNO-LIA indeterminate, and had no other positive HCV results. 
Twenty two percent (n=37) of participants infected through clotting factors had no RNA test results 
in their charts. All were deceased and most had died in the early to mid 1990s. RNA tests were only 
commonly used from 1994 onwards in Ireland. It is likely that a large proportion would have been RNA 
positive if they had been tested prior to their death.  
4.2.2 Viral clearance rate
Once participants with no RNA results were excluded (n=49), the overall spontaneous viral clearance rate, 
as determined by testing RNA negative at the time of first diagnosis, was 36% (458/1271). This varied 
by sex and source of infection. Females (n=421, 42%) were significantly more likely to have cleared the 
virus by the time of their diagnosis than males (n=37, 14%) (figure 4). This sex imbalance remained but 
was significantly lessened when anti-D participants were excluded (23% for females compared to 14% for 
males). 
As stated above, some participants did not have positive confirmatory results for HCV. A proportion of 
these may have had false positive ELISA/EIA results, making the viral clearance rate appear higher than 
it actually was. When only participants with positive confirmatory results for HCV were analysed, 20% 
(199/1012) had cleared the virus spontaneously by the time they were diagnosed. Therefore the true 
spontaneous viral clearance rate after the acute infection is likely to be between 20 and 36%, with 64%-
80% of infections becoming chronic.
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Figure 4. Hepatitis C RNA results for all participants and by sex 
- 28 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
4.3 End of latest follow-up 
Data up to the end of 2013, where available, were collected for this round of data collection. However, 
latest follow-up for each participant is effectively the last time they visited their hepatology unit, or their 
last test result or their date of death, as this is the last date when information was recorded in their 
medical charts. 
Sixty three percent of all living database participants had attended their hepatology unit in 2012 or 
2013 and a further 6% had been followed up through other services within the same hospital in this time 
period. Attendance at the hepatology units varied with RNA status. Seventy six percent of participants 
who remained chronically infected attended their unit in 2012 or 2013 and a further four percent were 
followed up through other services in the hospital. Seventy three percent of participants, who were 
chronically infected in the past and had cleared the virus, attended their unit in 2012 or 2013 and a further 
eight percent of these participants were followed up through other services in the hospital. Participants 
who had never become chronically infected were less likely to have attended recently, with 46% attending 
in 2012 or 2013 and an additional 8% attending other services in the hospital. It should be considered 
that some database participants are likely to have moved abroad and may be lost to follow-up and some 
of the participants who never became chronically infected may have been discharged to the care of their 
GPs. Thirty four living participants have been discharged from their hepatology unit. Twenty two never 
tested RNA positive, five had no RNA results in their charts, seven were chronically infected in the past 
but have since cleared the virus.
4.4 Database participants: entire cohort
Date of infection and demographic characteristics for the entire database cohort are shown in figure 5 and 
table 17. 
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Figure 5. Number of database participants by year of HCV infection and RNA status
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Table 17. Summary of demographic and virus characteristics for database participants by RNA status (n=1320)
All participants
 
All*
Ever 
chronically 
infected
Currently 
chronically 
infected
Alive & 
currently 
chronically 
infected
Chronically 
infected in 
the past
Never 
chronically 
infected
Num % Num % Num % Num % Num % Num %
All participants 1320  813  562  390  251  458  
Sex (n=1320)             
Females 1025 77.7 591 72.7 419 74.6 324 83.1 172 68.5 421 91.9
Males 295 22.3 222 27.3 143 25.4 66 16.9 79 31.5 37 8.1
Age at infection (n=1320)             
Median 28 0-77 28 0-77 29 0-77 28 0-72 26 0-66 28 0-63
<20 212 16.1 145 17.8 80 14.2 58 14.9 65 25.9 43 9.4
20-24 228 17.3 138 17.0 88 15.7 64 16.4 50 19.9 82 17.9
25-29 338 25.6 180 22.1 128 22.8 102 26.2 52 20.7 153 33.4
30-34 259 19.6 152 18.7 103 18.3 81 20.8 49 19.5 104 22.7
35-39 136 10.3 88 10.8 70 12.5 48 12.3 18 7.2 44 9.6
40+ 147 11.1 110 13.5 93 16.5 37 9.5 17 6.8 32 7.0
Age at end of follow-up (n=1320)             
Median 60 12-91 61 16-91 62 18-91 63 21-90 57 16-83 59 15-91
0-44 187 14.2 104 12.8 56 10.0 28 7.2 48 19.1 52 11.4
45-49 98 7.4 54 6.6 28 5.0 12 3.1 26 10.4 41 9.0
50-54 160 12.1 92 11.3 53 9.4 37 9.5 39 15.5 64 14.0
55-59 200 15.2 125 15.4 83 14.8 61 15.6 42 16.7 73 15.9
60-64 268 20.3 152 18.7 111 19.8 85 21.8 41 16.3 111 24.2
65-69 215 16.3 144 17.7 109 19.4 88 22.6 35 13.9 69 15.1
70+ 192 14.5 142 17.5 122 21.7 79 20.3 20 8.0 48 10.5
Time since infection (n=1320)             
Median 32 1-52 34 1-52 34 1-52 36 7-52 32 10-51 32 4-48
<20 years 165 12.5 85 10.5 63 11.2 12 3.1 22 8.8 59 12.9
20-29 years 368 27.9 209 25.7 127 22.6 63 16.2 82 32.7 135 29.5
30+ years 787 59.6 519 63.8 372 66.2 315 80.8 147 58.6 264 57.6
Duration RNA positivity (n=813)             
Median 31 1-52 31 1-52 34 1-52 36 7-52 22 1-45  n/a  
<20 years 169 20.8 169 20.8 63 11.2 12 3.1 106 42.2   
20-29 years 207 25.5 207 25.5 127 22.6 63 16.2 80 31.9   
30+ years 437 53.8 437 53.8 372 66.2 315 80.8 65 25.9   
Highest alcohol intake (n=1207)             
Non drinker 289 23.9 177 23.1 131 24.9 85 22.5 46 19.3 106 25.1
Within recommended limits 741 61.4 455 59.5 301 57.1 240 63.7 154 64.7 278 65.7
Moderately high 85 7.0 60 7.8 35 6.6 25 6.6 25 10.5 24 5.7
High† 92 7.6 73 9.5 60 11.4 27 7.2 13 5.5 15 3.5
HCV genotype (n=781)             
Genotype 1 598 76.6 598 76.6 465 85.3 348 89.5 133 56.4  n/a  
Genotype 2 37 4.7 37 4.7 16 2.9 8 2.1 21 8.9   
Genotype 3 142 18.2 142 18.2 61 11.2 32 8.2 81 34.3   
Genotype 4 2 0.3 2 0.3 2 0.4 1 0.3 0 0.0   
Genotype 5 2 0.3 2 0.3 1 0.2 0 0 1 0.4   
Body mass index (n=585)             
Normal or underweight 194 33.2 131 32.9 98 35.5 84 34.9 33 27.0 63 33.7
Overweight 216 36.9 151 37.9 107 38.8 94 39.0 44 36.1 65 34.8
Obese 175 29.9 116 29.1 71 25.7 63 26.1 45 36.9 59 31.6
- 30 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
* 49 database participants had no RNA results in their medical records. They are included in the data for the “All” category, but not 
in the breakdown by RNA status.
†  High alcohol intake includes alcohol abuse or alcoholic liver disease recorded in participant’s medical record. The alcohol 
breakdown represents the highest recorded alcohol intake for each participant. No alcohol data were available for 113 database 
participants.
n/a: not applicable 
4.4.1 Sex, age and duration of infection
See Methods section 3.3 for assumptions about year of infection. 
Of the 1320 database participants, 62% (n=813) were chronically HCV infected at diagnosis. Due to 
the large anti-D cohort, females predominate and account for 73% (n=591) of those who ever became 
chronically infected and 83% (n=324) of those who remained chronically infected and alive at the end of 
latest follow-up. The median age at infection for ever chronically infected participants was 28 years, the 
median age at end of follow-up was 61 years and the median duration of RNA positivity was 31 years. 
Those remaining chronically infected and alive at the latest follow-up (n=390) are now a median age of 63 
years and have been infected for a median duration of 36 years (table 17). Eighty one percent of these 
have been HCV RNA positive for 30 years or longer.
4.4.2 Alcohol consumption
See Methods section 3.7 for categorization of alcohol consumption. 
Moderately high alcohol intake was recorded in the medical charts of 8% of ever chronically infected 
participants for whom data were available, and high alcohol consumption was recorded for 10% (table 
17). Males and females differed in their reported exposure to alcohol with 34% (n=68) of chronically 
infected males having moderately high or high alcohol intake compared to 12% (n=65) of females (figure 
6). Younger participants were also more likely to drink excessively. Alcohol consumption also differed 
significantly by source of infection with participants infected through anti-D (11%) (table 19) less likely to 
consume alcohol in excess of recommendations compared to those infected through blood transfusion or 
treatment for renal disease (21%) (table 20) and those infected through clotting factors (35%) (table 21). 
However, this is largely attributable to the differences in age and sex distribution by source of infection.
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Figure 6. Distribution of highest reported alcohol consumption by sex for participants who became chronically 
infected (n=765)
4.4.3 HCV genotype
The HCV genotype was available for nearly all of the database participants who became chronically 
infected (n=781, 96%). Genotype 1 predominated: 77% (n=598) were infected with genotype 1, 18% 
(n=142) were infected with genotype 3, 5% (n=37) were infected with genotype 2 and four participants 
were infected with genotypes 4 or 5 (table 17). 
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4.4.4 Body mass index (BMI)
BMI data were available for 44% (n=585) of all database participants and 49% (n=398) of ever chronically 
infected participants.  Overall, 37% (n=216) were overweight and a further 30% (n=175) were obese (table 
17). These data may not be representative of all participants as it is likely that BMI data are recorded 
more often for those who are either overweight or underweight. BMI did not vary significantly by sex 
or source of infection, but did vary by age at end of latest follow-up, with participants aged between 
50 and 64 years more likely to be obese than both younger and older participants. BMI did not vary by 
HCV RNA status except for patients who were chronically infected and have now cleared the virus. These 
patients were more likely to be obese than currently chronically infected participants and those who never 
became chronically infected. However, this may be associated with HCV genotype as genotype 3 patients 
were more likely to be obese and were also more likely to have been successfully treated compared to 
genotype 1 patients. It could also indicate that people who had not yet cleared the virus had adopted 
healthier diets with the knowledge that obesity can accelerate liver disease progression. Alternatively, 
this could be a data anomaly due to greater BMI data completeness for genotype 1 participants (53% 
compared to 39% for genotype 3 participants, p=0.002). 
4.4.5 Diabetes mellitus and steatosis
Diabetes was recorded in the medical charts of 8% (n=105) of database participants. The prevalence 
varied by RNA status, with those who became chronically infected more likely to have diabetes than those 
who never developed chronic infection (9.6% compared to 5.5%, p=0.009) (table 18). The prevalence 
of diabetes increased significantly with increasing BMI only for participants who were never chronically 
infected, and obesity and older age were the only demographic factors independently associated with 
diabetes in this population on logistic regression analysis. For chronically infected participants, the 
prevalence of diabetes varied by age and sex, with males and older people (≥50 years) more likely to 
be diabetic. There was no significant variation in diabetes by HCV genotype or BMI. However, BMI data 
were only available for 49% of chronically infected participants, so this finding may be due to poor data 
completeness.
A further sixteen participants did not have a diagnosis of diabetes recorded in their medical records but 
did have test results indicating potential diabetes: six had haemoglobin A1c results of 48 mmol/mol or 
greater, five had fasting blood glucose levels ≥7 mmol/l and five had random blood glucose levels ≥11.1 
mmol/l. Eleven were chronically HCV infected and five were never chronically infected.
Table 18. Comparison of the prevalence of diabetes mellitus in ever and never chronically infected 
participants (chi-square test), by BMI, sex, source of infection, age at end of follow-up and HCV genotype
Diabetes 
 
Ever chronically 
infected
Never chronically 
infected p-value
Num % Num %  
All participants (n=1271) 78 9.6 25 5.5 0.009
BMI category (n=585)      
Underweight or normal 11 8.4 0 0 0.018
Overweight 17 11.3 4 6.2 0.245
Obese 15 12.9 12 20.3 0.200
Sex (n=1271)      
Females 51 8.6 22 5.2 0.039
Males 27 12.2 3 8.1 0.476
Source of infection (n=1313)      
Anti-D all 40 9.4 18 4.8 0.014
Anti-D 77-79 37 9.9 16 5.3 0.027
Anti-D 91-94 2 5.4 0 0 0.182
Transfusion or renal 31 11.3 6 9.8 0.739
Clotting factors 7 6.5 1 4.8 0.758
Age at end of latest follow-up (years) (n=1271)      
0-49 7 4.4 0 0.0 0.040
50-64 39 10.6 10 4.0 0.003
65+ 32 11.2 15 12.8 0.643
Note: Two database participants with diabetes did not have RNA results recorded and are not included in this table
- 32 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Steatosis was recorded in the medical records of 15% (n=120) of participants who were ever chronically 
infected with HCV, and of 19% (n=73) of those who remained chronically infected and alive at latest 
follow-up. This is likely to be an underestimate as steatosis may remain undiagnosed in patients who have 
not had recent ultrasounds, biopsies, MRI or CT scans. Sixty two percent (n=227) of participants who 
remain chronically infected and alive, and had not previously been diagnosed with steatosis, had one or 
more of these procedures in the past four years. Twenty percent (n=46) were diagnosed with steatosis as a 
result. In those who remain chronically infected and alive, steatosis was significantly associated with being 
overweight or obese and with having high fibrosis scores on biopsy on multivariable logistic regression 
analysis. Steatosis was not independently associated with sex, high alcohol consumption or HCV genotype 
once BMI and fibrosis scores were taken into account. 
4.5 Description of database participants by source of infection
4.5.1 Participants infected through contaminated anti-D immunoglobulin (n=811)
The anti-D group is entirely composed of females who were infected during their child-bearing years 
(median age at infection: 28 years) (figure 7, table 19). As a group, they would be expected to have been 
relatively healthy when infected. Infection due to contaminated anti-D has been largely traced to batches 
of anti-D from two infected donors.27 Batches from the first donor were contaminated with genotype 1 
HCV and were distributed between 1977 and 1979. Eighty four percent (n=682) of anti-D participants 
were infected during this period. Batches from the second donor were infected with genotype 3 HCV. 
These were administered between 1991 and 1994 and accounted for nine percent (n=73) of participating 
anti-D participants. The genotype for six additional participants infected between 1991 and 1994 did 
not match the outbreak genotype. The estimated year of infection for the remaining fifty participants 
was outside of the two outbreak periods and sixty six percent of these (n=33) did not have positive 
confirmatory results for HCV. The source of their infection is unclear. By latest follow-up, 32% (n=261) 
of anti-D participants remained chronically infected and alive. The median age of this subset of the 
population was 63 years and their median duration of RNA positivity was 36 years. Ninety four percent 
had been RNA positive for 30 years or longer. Detailed results by each outbreak are contained in Table 32.
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Figure 7. Number of anti-D participants by year of HCV infection and RNA status
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Table 19. Summary of demographic and virus characteristics for all anti-D database participants by 
RNA status (n=811)
Anti-D all
 
All*
Ever 
chronically 
infected
Currently 
chronically 
infected
Alive & 
currently 
chronically 
infected
Chronically 
infected in 
the past
Never 
chronically 
infected
Num % Num % Num % Num % Num % Num %
All participants 811  428  312  261  116  373  
Sex (n=811)             
Females 811 100 428 100 312 100 261 100 116 100 373 100
Males 0 0 0 0 0 0 0 0 0 0 0 0
Age at infection (n=811)             
Median (range) 28 17-44 28 17-44 28 17-44 28 17-44 27.5 17-39 28 17-43
<20 45 5.5 24 5.6 18 5.8 15 5.7 6 5.2 21 5.6
20-24 176 21.7 98 22.9 64 20.5 54 20.7 34 29.3 73 19.6
25-29 279 34.4 136 31.8 101 32.4 87 33.3 35 30.2 140 37.5
30-34 200 24.7 103 24.1 73 23.4 66 25.3 30 25.9 96 25.7
35-39 90 11.1 58 13.6 47 15.1 32 12.3 11 9.5 31 8.3
40+ 21 2.6 9 2.1 9 2.9 7 2.7 0 0.0 12 3.2
Age at end of follow-up 
(n=811)
            
Median (range) 61 26-80 62 31-79 63 33-79 63 34-79 59 31-75 60 26-80
0-44 51 6.3 16 3.7 6 1.9 4 1.5 10 8.6 31 8.3
45-49 53 6.5 20 4.7 11 3.5 4 1.5 9 7.8 32 8.6
50-54 106 13.1 45 10.5 25 8.0 20 7.7 20 17.2 59 15.8
55-59 149 18.4 84 19.6 60 19.2 49 18.8 24 20.7 64 17.2
60-64 211 26.0 111 25.9 82 26.3 70 26.8 29 25.0 98 26.3
65-69 159 19.6 101 23.6 81 26.0 72 27.6 20 17.2 58 15.5
70+ 82 10.1 51 11.9 47 15.1 42 16.1 4 3.4 31 8.3
Time since infection (n=811)             
Median 35 4-52 36 9-52 36 9-52 36 9-52 35 10-37 34 4-48
<20 years 57 7.0 18 4.2 5 1.6 3 1.1 13 11.2 36 9.7
20-29 years 165 20.3 60 14.0 33 10.6 14 5.4 27 23.3 101 27.1
30+ years 589 72.6 350 81.8 274 87.8 244 93.5 76 65.5 236 63.3
Duration RNA positivity 
(n=428)
            
Median 35 1-52 35 1-52 36 9-52 36 9-52 23 1-36 n/a  
<20 years 57 13.3 57 13.3 5 1.6 3 1.1 52 44.8   
20-29 years 60 14.0 60 14.0 33 10.6 14 5.4 27 23.3   
30+ years 311 72.7 311 72.7 274 87.8 244 93.5 37 31.9   
Highest alcohol intake (n=777)             
Non drinker 169 21.8 80 19.1 60 19.6 48 18.7 20 17.9 88 24.9
Within recommended limits 541 69.6 292 69.9 211 69.0 186 72.4 81 72.3 246 69.7
Moderately high 35 4.5 22 5.3 16 5.2 13 5.1 6 5.4 13 3.7
High 32 4.1 24 5.7 19 6.2 10 3.9 5 4.5 6 1.7
HCV genotype (n=423)             
Genotype 1 380 89.8 380 89.8 304 98.4 256 98.1 76 66.7 n/a  
Genotype 2 2 0.5 2 0.5 0 0.0 0 0.0 2 1.8   
Genotype 3 41 9.7 41 9.7 5 1.6 5 1.9 36 31.6   
Genotype 4             
Genotype 5             
Body mass index (n=410)             
Normal or underweight 133 32.4 76 30.4 59 30.9 50 28.7 17 28.8 57 35.6
Overweight 153 37.3 97 38.8 80 41.9 74 42.5 17 28.8 56 35.0
Obese 124 30.2 77 30.8 52 27.2 50 28.7 25 42.4 47 29.4
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*1 0 Anti-D database participants had no RNA results in their medical records. They are included in the data for the “All” category, 
but not in the breakdown by RNA status. Eleven genotype 1 anti-D participants, 2 genotype 2 anti-D participants and 4 genotype 
3 anti-D participants either had a genotype that did not match that of their outbreak periods or were infected outside of outbreak 
periods
n/a: not applicable
4.5.2 Participants infected through contaminated blood transfusions or treatment for renal disease 
(n=337)
This group was the most heterogeneous in terms of age and sex (table 20). They had the highest median 
age at infection (32), but this ranged from 0 to 77 years. Fifty nine percent of chronically infected 
participants were female and forty one percent were male, making this the only group with sizeable 
proportions of each sex. Using the assumptions outlined in Methods section 3.3, most of the blood 
transfusion/renal participants were infected in the late 1970s and 1980s. At latest follow-up, the median 
age of transfusion/renal participants who remained chronically infected and alive (29%, n=99) was 66 years 
and the median duration of RNA positivity was 29 years. They had the shortest duration of RNA positivity 
at latest follow-up, with 46% positive for 30 years or longer and 71% positive for 25 years or longer.
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Figure 8. Number of transfusion or renal participants by year of HCV infection and RNA status
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Table 20. Summary of demographic and virus characteristics for transfusion or renal database 
participants by RNA status
Transfusion or renal
 
All*
Ever 
chronically 
infected
Currently 
chronically 
infected
Alive & 
currently 
chronically 
infected
Chronically 
infected in 
the past
Never 
chronically 
infected
Num % Num % Num % Num % Num % Num %
All participants 337  274  186  99  88  61  
Sex (n=337)             
Females 198 58.8 153 55.8 101 54.3 60 60.6 52 59.1 44 72.1
Males 139 41.2 121 44.2 85 45.7 39 39.4 36 40.9 17 27.9
Age at infection (n=337)             
Median 32 0-77 32 0-77 36 0-77 32 0-72 27.5 0.7 34 0-63
<20 52 15.4 46 16.8 23 12.4 20 20.2 23 26.1 6 9.8
20-24 34 10.1 27 9.9 14 7.5 7 7.1 13 14.8 7 11.5
25-29 48 14.2 37 13.5 23 12.4 14 14.1 14 15.9 11 18.0
30-34 48 14.2 41 15.0 26 14.0 13 13.1 15 17.0 7 11.5
35-39 40 11.9 29 10.6 22 11.8 16 16.2 7 8.0 10 16.4
40+ 115 34.1 94 34.3 78 41.9 29 29.3 16 18.2 20 32.8
Age at end of follow-up (n=337)             
Median 63 16-91 63 16-91 65 21-91 66 21-90 56.5 16-83 62 16-91
0-44 50 14.8 42 15.3 24 12.9 13 13.1 18 20.5 8 13.1
45-49 26 7.7 19 6.9 10 5.4 4 4.0 9 10.2 7 11.5
50-54 33 9.8 30 10.9 18 9.7 11 11.1 12 13.6 3 4.9
55-59 34 10.1 26 9.5 15 8.1 9 9.1 11 12.5 8 13.1
60-64 43 12.8 33 12.0 23 12.4 12 12.1 10 11.4 10 16.4
65-69 49 14.5 38 13.9 26 14.0 15 15.2 12 13.6 10 16.4
70+ 102 30.3 86 31.4 70 37.6 35 35.4 16 18.2 15 24.6
Time since infection (n=337)             
Median 26 1-51 26 1-51 25 1-49 29 7-49 28 14-51 24 7-42
<20 years 81 24.0 61 22.3 53 28.5 9 9.1 8 9.1 19 31.1
20-29 years 147 43.6 119 43.4 76 40.9 44 44.4 43 48.9 28 45.9
30+ years 109 32.3 94 34.3 57 30.6 46 46.5 37 42.0 14 23.0
Duration RNA positivity (n=274)             
Median 22 1-49 22 1-49 25 1-49 29 7-49 19.5 4-41 n/a  
<20 years 97 35.4 97 35.4 53 28.5 9 9.1 44 50.0   
20-29 years 108 39.4 108 39.4 76 40.9 44 44.4 32 36.4   
30+ years 69 25.2 69 25.2 57 30.6 46 46.5 12 13.6   
Highest alcohol intake (n=303)             
Non drinker 96 31.7 79 31.5 61 36.5 32 34.8 18 21.4 16 31.4
Within recommended limits 142 46.9 119 47.4 67 40.1 39 42.4 52 61.9 23 45.1
Moderately high 26 8.6 20 8.0 11 6.6 7 7.6 9 10.7 6 11.8
High 39 12.9 33 13.1 28 16.8 14 15.2 5 6.0 6 11.8
HCV genotype (n=262)             
Genotype 1 154 58.8 154 58.8 121 66.9 71 71.7 33 40.7 n/a  
Genotype 2 26 9.9 26 9.9 13 7.2 7 7.1 13 16.0   
Genotype 3 81 30.9 81 30.9 46 25.4 21 21.2 35 43.2   
Genotype 4 1 0.4 1 0.4 1 0.6       
Genotype 5             
Body mass index (n=132)             
Normal or underweight 49 37.1 45 40.2 31 47.7 27 52.9 14 29.8 4 20.0
Overweight 48 36.4 40 35.7 20 30.8 14 27.5 20 42.6 8 40.0
Obese 35 26.5 27 24.1 14 21.5 10 19.6 13 27.7 8 40.0
* 2 transfusion or renal database participants had no RNA results in their medical records. They are included in the data for the “All” 
category, but not in the breakdown by RNA status
n/a: not applicable
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4.5.3 Participants infected through contaminated blood clotting factors (n=165)
Participants infected through clotting factors were predominantly male (93%, n=154) (table 21). Using the 
assumptions outlined in Methods section 3.3, most were infected as children in the mid-1970s to early 
1980s (figure 9). The median age at infection was 13 years for the group as a whole and 14 years for 
those who were chronically infected. By latest follow-up, the median age for clotting factor participants 
who remained chronically infected and alive (17%, n=28) was 50 years and the median duration of RNA 
positivity was 38 years. Eighty six percent had been RNA positive for 30 years or longer (table 21). Forty 
two percent (n=69) of all clotting factor participants were co-infected with HIV and 32% (n=22) were alive 
at latest follow-up. Of these 22 participants, 9 remain currently chronically infected with HCV, 12 have 
cleared the virus through treatment and one was never chronically infected.
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Figure 9. Number of clotting factor participants by year of HCV infection and RNA status
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Table 21. Summary of demographic and virus characteristics for clotting factor database participants 
by RNA status
Clotting factors
 
All*
Ever 
chronically 
infected
Currently 
chronically 
infected
Alive & 
currently 
chronically 
infected
Chronically 
infected in the 
past
Never 
chronically 
infected
 Num % Num % Num % Num % Num % Num %
All participants 165  107  61  28  46  21  
Sex (n=165)             
Females 11 6.7 7 6.5 3 4.9 1 3.6 4 8.7 2 9.5
Males 154 93.3 100 93.5 58 95.1 27 96.4 42 91.3 19 90.5
Age at infection (n=165)             
Median 13 0-59 14 0-53 16 0-53 13.5 1-42 12 0-33 12 0-38
<20 111 67.3 73 68.2 37 60.7 21 75.0 36 78.3 14 66.7
20-24 18 10.9 13 12.1 10 16.4 3 10.7 3 6.5 2 9.5
25-29 11 6.7 7 6.5 4 6.6 1 3.6 3 6.5 2 9.5
30-34 11 6.7 8 7.5 4 6.6 2 7.1 4 8.7 1 4.8
35-39 5 3.0 1 0.9 1 1.6     2 9.5
40+ 9 5.5 5 4.7 5 8.2 1 3.6     
Age at end of follow-up 
(n=165)
            
Median 44 12-81 46 18-81 49 18-81 50 30-81 45.5 30-66 43 26-71
0-44 83 50.3 45 42.1 25 41.0 10 35.7 20 43.5 11 52.4
45-49 18 10.9 14 13.1 6 9.8 3 10.7 8 17.4 2 9.5
50-54 21 12.7 17 15.9 10 16.4 6 21.4 7 15.2 2 9.5
55-59 17 10.3 15 14.0 8 13.1 3 10.7 7 15.2 1 4.8
60-64 14 8.5 8 7.5 6 9.8 3 10.7 2 4.3 3 14.3
65-69 6 3.6 4 3.7 2 3.3 1 3.6 2 4.3 1 4.8
70+ 6 3.6 4 3.7 4 6.6 2 7.1   1 4.8
Time since infection (n=165)             
Median 30 8-50 33 14-50 33 14-50 38 23-43 35.5 20-48 32 15-43
<20 years 24 14.5 5 4.7 5 8.2     2 9.5
20-29 years 54 32.7 28 26.2 16 26.2 4 14.3 12 26.1 6 28.6
30+ years 87 52.7 74 69.2 40 65.6 24 85.7 34 73.9 13 61.9
Duration RNA positivity 
(n=107)
            
Median 30 4-50 30 4-50 33 14-50 38 23-43 27 4-45  n/a  
<20 years 14 13.1 14 13.1 5 8.2   9 19.6   
20-29 years 37 34.6 37 34.6 16 26.2 4 14.3 21 45.7   
30+ years 56 52.3 56 52.3 40 65.6 24 85.7 16 34.8   
Highest alcohol intake 
(n=123)
            
Non drinker 23 18.7 17 18.3 9 17.6 4 15.4 8 19.0 2 11.1
Within recommended limits 56 45.5 43 46.2 22 43.1 14 53.8 21 50.0 8 44.4
Moderately high 24 19.5 18 19.4 8 15.7 5 19.2 10 23.8 5 27.8
High 20 16.3 15 16.1 12 23.5 3 11.5 3 7.1 3 16.7
HCV genotype (n=92)             
Genotype 1 60 65.2 60 65.2 37 71.2 19 70.4 23 57.5  n/a  
Genotype 2 9 9.8 9 9.8 3 5.8 1 3.7 6 15.0   
Genotype 3 20 21.7 20 21.7 10 19.2 6 22.2 10 25.0   
Genotype 4 2 2.2 2 2.2 2 3.8 1 3.7     
Genotype 5 1 1.1 1 1.1 0 0.0 0 0.0 1 2.5   
Body mass index (n=40)             
Normal or underweight 11 27.5 10 27.8 8 40.0 7 43.8 2 12.5 1 25.0
Overweight 14 35.0 14 38.9 7 35.0 6 37.5 7 43.8   
Obese 15 37.5 12 33.3 5 25.0 3 18.8 7 43.8 3 75.0
*37 clotting factor database participants had no RNA results in their medical records. They are included in the data for the “All” 
category, but not in the breakdown by RNA status. All 37 are deceased and 31 were HIV positive.
n/a: not applicable
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4.6 Outcomes
Summary table 1 shows that liver-related disease was rare in those who did not develop chronic HCV 
infection, therefore the focus of this results section is those participants who developed chronic infection.
4.6.1 Clinical signs of serious liver disease
Twenty nine percent (n=233) of chronically infected participants had one or more clinical signs of serious 
liver disease (as listed in table 22) recorded in their charts by latest follow-up. The most common 
conditions or signs recorded were cirrhosis, varices, portal hypertension and ascites. 
Table 22. Number and percentage of participants with clinical signs of serious liver disease by RNA 
status*
Clinical signs of liver disease
 
All 
participants
Ever 
chronically 
infected
Currently 
chronically 
infected
Alive & 
currently 
chronically 
infected
Chronically 
infected in 
past
Never 
chronically 
infected
Num % Num % Num % Num % Num % Num %
One or more signs of serious 
liver disease
246 18.6 233 28.7 186 33.1 91 23.3 47 18.7 6 1.3
Cirrhosis 188 14.2 181 22.3 144 25.6 65 16.7 37 14.7 2 0.4
Varices 84 6.4 82 10.1 70 12.5 31 7.9 12 4.8 0 0
Portal Hypertension 77 5.8 76 9.3 65 11.6 30 7.7 11 4.4 0 0
Ascites 71 5.4 67 8.2 62 11.0 18 4.6 5 2.0 3 0.7
Splenomegaly 68 5.2 67 8.2 54 9.6 32 8.2 13 5.2 1 0.2
Liver Tumour/HCC 46 3.5 44 5.4 43 7.7 9 2.3 1 0.4 0 0
Hepatomegaly 36 2.7 33 4.1 27 4.8 9 2.3 6 2.4 3 0.7
Encephalopathy 27 2.0 25 3.1 24 4.3 7 1.8 1 0.4 1 0.2
Bleeding Varices 14 1.1 13 1.6 13 2.3 4 1 0 0 0 0
Decompensated Liver Disease 14 1.1 13 1.6 12 2.1 3 0.8 1 0.4 0 0
Hepatosplenomegaly 6 0.5 6 0.7 4 0.7 1 0.3 2 0.8 0 0
Hypersplenism 5 0.4 5 0.6 4 0.7 2 0.5 1 0.4 0 0
Hepatic Synthetic Dysfunction 1 0.1 1 0.1 1 0.2 0 0 0 0 0 0
Hepatopulmonary Syndrome 1 0.1 1 0.1 1 0.2 0 0 0 0 0 0
Portal Gastropathy 1 0.1 1 0.1 0 0 0 0 1 0.4 0 0
Hepato Renal Syndrome 1 0.1 1 0.1 1 0.2 1 0.3 0 0 0 0
*7 participants with one or more signs of liver disease (including 5 with cirrhosis) had no RNA results in their charts
The factors independently associated with having one or more clinical signs of serious liver disease on 
logistic regression analysis were high alcohol intake, longer duration of RNA positivity, male sex, older age 
at end of follow-up and genotype 3 (rather than genotype 1) HCV infection (table 23 – logistic regression 
model a). Participants with high alcohol consumption had more than five times higher odds of having 
signs of liver disease compared to those without. However, the number of chronically infected participants 
with high alcohol intake was low (n=73, 9.5%) and due to its sensitivity, alcohol consumption data may be 
inaccurately reported.
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Table 23. Factors associated with having one or more clinical signs of serious liver disease in ever 
chronically infected participants – logistic regression model a (n=736)
 Factors associated with clinical signs of serious liver disease Odds ratio p-value
95% confidence 
interval
Highest recorded alcohol consumption    
 Non drinker/within recommended limits/moderately high 1   
High (>40 units per week or alcohol abuse in chart) 5.2 <0.001 2.96 - 9.09
Duration of RNA positivity    
<20 years 1   
20+ years 3.1 <0.001 1.80 - 5.48
Sex    
Female 1   
Male 2.3 <0.001 1.51 - 3.51
Age at end of latest follow-up (years)    
0-49 years 1   
50-64 years 1.8 0.037 0.34 - 2.09
65+ years 1.9 0.024 1.02 - 2.80
Genotype    
Genotype 1 1   
Genotype 2 0.8 0.716 0.34 - 2.09
Genotype 3 1.7 0.04 1.02 - 2.80
Explanatory note: The odds ratios shown are a measure of the odds of clinical signs of serious liver disease in one group (e.g. males) 
divided by the odds of serious disease in another group (the reference group e.g. females). An odds ratio of 1 indicates that signs 
of liver disease are equally likely in both males and females and on odds ratio of greater than 1 for males indicates that signs of liver 
disease are more likely in males. P-values of <0.05 were taken to indicate a statistically significant difference between the distribution 
of signs of liver disease in the category of the factor being assessed and the reference category of that factor.
The effects of source of infection and sex cannot be assessed in the same logistic regression model as sex 
is too closely linked to source of infection in the database population. Genotype and older age at end of 
follow-up are not independently associated with clinical signs of serious disease when source of infection 
is included in the logistic regression model instead of sex. Blood transfusion/renal participants are 
significantly more likely to have one or more signs of liver disease compared to anti-D participants (table 
24 – logistic regression model b).
Table 24. Factors associated with having one or more clinical signs of serious liver disease in ever 
chronically infected participants – logistic regression model b (n=762)
 Factors associated with clinical signs of serious liver disease Odds ratio p-value
95% 
confidence 
interval
Highest recorded alcohol consumption    
 Non drinker/within recommended limits/moderately high 1   
High (>40 units per week or alcohol abuse in chart) 5.2 <0.001 3.04 - 8.85
Duration of RNA positivity    
<20 years 1   
20+ years 3 <0.001 1.83 - 4.96
Source of infection    
Anti-D 1   
Transfusion or renal 2.3 <0.001 1.57 - 3.32
Clotting factors 1.6 0.064 0.97 - 2.70
Figures 10 and 11 show the prevalence of clinical signs of serious liver disease by duration of RNA 
positivity and alcohol intake, by sex and source of infection separately.
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Figure 10. Percentage of ever chronically infected participants with one or more clinical signs of serious liver 
disease, by sex, duration of RNA positivity and alcohol consumption
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Figure 11. Percentage of ever chronically infected participants with one or more clinical signs of serious liver 
disease, by source of infection, duration of RNA positivity and alcohol consumption
4.6.2 Cirrhosis
Cirrhosis varied significantly by RNA status, with ever chronically infected participants significantly more 
likely to have developed cirrhosis compared to those who never became chronically infected (n=181, 
22.3% compared to n=2, 0.4%, p<0.001). Those who were chronically infected on last RNA test had 
significantly higher prevalence of cirrhosis than those with past chronic infection (n=144, 25.6% compared 
to n=37, 14.7%, p=0.001) (table 25, figure 12). 
Of the 37 participants with cirrhosis who have cleared the virus, 30 had developed cirrhosis prior to viral 
clearance (see Methods section 3.4 regarding the method of assigning dates of diagnosis). The median 
time between viral clearance and developing cirrhosis for the remaining seven was nine years (range: 2-13 
years). Three of these participants had high alcohol intake, three had high fibrosis scores on pre-treatment 
biopsies and the remaining patient had not had a biopsy in the six years prior to viral clearance. 
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For ever chronically infected database participants, the median duration of RNA positivity at the estimated 
date of cirrhosis (see Methods section 3.4 and 3.5 for methods used) was 26 years (mean: 25.1 years) and 
the median age at cirrhosis was 55 years (mean: 55.4 years). On univariate analysis of ever chronically 
infected participants, the prevalence of cirrhosis was significantly higher in blood transfusion/renal 
participants compared to those infected through either anti-D or clotting factors. It was also higher in 
participants who had high alcohol intake recorded in their medical notes (table 25). Where alcohol data 
were recorded, 22% of ever chronically infected participants with cirrhosis had consumed over 40 units 
of alcohol per week or had alcohol abuse or alcoholic liver disease recorded in their charts at some stage 
compared to 6% of ever chronically infected participants without cirrhosis. 
Table 25. Cirrhosis in ever chronically infected database participants (with univariate chi-square test for 
differences in prevalence of cirrhosis across different categories of host and virus variables)
 Ever chronically infected database 
participants
Number 
with 
cirrhosis
% with 
cirrhosis
Median age 
at cirrhosis 
diagnosis (years)
Median duration 
RNA positivity at 
cirrhosis (years)
p-value
All 181 22.3 55 26  
Sex     0.070
Females 122 20.6 59 27  
Males 59 26.6 51 24  
Source of infection     0.001
Anti-D all 77 18.0 56 30  
Anti-D 77-79 72 19.3 57 30  
Anti-D 91-94 3 8.1 42 12  
Transfusion or renal 82 29.9 57 22  
Clotting factors 21 19.6 45 30  
Highest recorded alcohol intake     <0.001
Non drinker 43 24.3 59 27  
Within recommended limits 77 16.9 56 27  
Moderately high 12 20.0 55 30  
High 38 52.1 54 22  
BMI     0.348
Normal or underweight 24 18.3 56 28  
Overweight 35 23.2 59 30  
Obese 30 25.9 55 26  
Age at end of latest follow-up (years)     0.059
0-49 years 24 15.2 39 23  
50-64 years 88 23.9 53 26  
65+ years 69 24.1 65 27  
RNA status at latest follow-up     0.001
Past chronic infection, cleared virus 37 14.7 55 30  
Currently chronically infected 144 25.6 56 32  
HCV genotype     0.848
Genotype 1 130 21.7 56 29  
Genotype 2 8 21.6 53 22  
Genotype 3 34 23.9 52 20  
High alcohol intake (OR 5.0, p<0.001), being 50 years or older at the end of latest follow-up (OR 2.4, 
p=0.002), being infected for 20 years or longer (OR 2.1, p=0.005) and male sex (OR 1.7, p=0.012), were 
all independently associated with higher prevalence of cirrhosis in ever chronically infected participants 
on multivariate logistic regression analysis. When source of infection was substituted for sex in the model, 
participants infected through blood transfusions or treatment for renal disease were significantly more 
likely to have developed cirrhosis compared to those infected through anti-D. 
Cox multivariate regression analysis was used to look at factors associated with the higher cirrhosis 
rates. Participants who remained chronically infected (hazard ratio 1.8, p=0.003), those with high alcohol 
consumption (hazard ratio 3.0, p<0.001), those infected through blood transfusions or treatment for renal 
disease (hazard ratio 2.4, p<0.001) and those with genotype 3 HCV infection (compared to genotype 1) 
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(hazard ratio 1.8, p=0.008) had higher rates of cirrhosis. Although males had higher rates of cirrhosis than 
females, the difference was not statistically significant after adjusting for RNA status, alcohol consumption 
and genotype.
Figure 12. Proportion of participants who have not developed cirrhosis over the follow-up period by RNA status 
– Kaplan Meier estimates
4.6.3 Hepatocellular carcinoma (HCC)/liver cancer 
By latest follow-up, 44 (5%) ever chronically infected participants and two participants with no RNA results 
had developed HCC. There were no cases of HCC in those who never developed chronic infection.
Thirty seven of the 46 participants (80.4%) with HCC were known to be deceased. The cause of death 
was directly liver-related for twenty eight, not directly liver-related for six and the death certificate was 
missing for the remaining three participants. The median time from date of diagnosis of cirrhosis to date 
of diagnosis of HCC was three years (see Methods section 3.4 regarding the method of assigning dates of 
diagnosis). Cirrhosis was not specifically mentioned in the medical records of five of the participants with 
HCC. However, two of these had ascites and one had varices. See section 4.12 below on liver transplants.
For ever chronically infected database participants, the median duration of RNA positivity at date of 
diagnosis of HCC was 29.5 years (mean: 27.7 years) and the median age at HCC was 62.5 years (mean: 
61 years) (see Methods sections 3.4 and 3.5 regarding methods used). On univariate analysis of ever 
chronically infected participants, the prevalence of HCC was significantly higher in blood transfusion/
renal and clotting factor participants compared to those infected through anti-D. It was also significantly 
higher in males compared to females, and in participants who had high alcohol intake recorded in their 
medical notes (table 26). Where alcohol data were recorded, 24% of ever chronically infected participants 
with HCC had consumed over 40 units of alcohol per week or had alcohol abuse or alcoholic liver disease 
recorded in their charts at some stage compared to 9% of ever chronically infected participants without 
HCC. 
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Table 26. Hepatocellular carcinoma (HCC) in ever chronically infected database participants, (with 
univariate chi-square test for differences in prevalence of HCC across different categories of host and virus 
variables)
 Ever chronically infected database 
participants
Number with 
HCC
% with HCC
Median 
age at HCC 
diagnosis 
(years)
Median 
duration RNA 
positivity at 
HCC (years)
p-value
All 44 5.4 62.5 29.5  
Sex     <0.001
Females 18 3.1 67.5 29.5  
Males 26 11.7 57 29.5  
Source of infection     <0.001
Anti-D all 7 1.6 66 32  
Anti-D 77-79 7 1.9 66 32  
Anti-D 91-94 0 0.0    
Transfusion or renal 27 9.9 68 25  
Clotting factors 10 9.4 53.5 31  
Highest recorded alcohol intake     0.005
Non drinker 11 6.2 68 32  
Within recommended limits 17 3.7 60 29  
Moderately high 3 5.0 53 29  
High 10 13.7 59 29  
BMI     0.36
Normal or underweight 4 3.1 60.5 25.5  
Overweight 10 6.6 67 30  
Obese 5 4.3 53 32  
Age at end of latest follow-up (years)     0.339
0-49 7 4.4 45 27  
50-64 17 4.6 55 30  
65+ 20 7.0 71 29.5  
RNA status at latest follow-up     <0.001
Past chronic infection, cleared virus 1 0.4 ~ ~  
Currently chronically infected 43 7.7 63 30  
HCV genotype     0.089*
Genotype 1 27 4.5 62 32  
Genotype 2 2 5.4 52 29.5  
Genotype 3 13 9.2 63 22  
* When comparing genotype 3 to genotype 1, there is a significant difference in prevalence of HCC p=0.028
~ Data on median age and median duration of RNA positivity not presented as only one participant who was chronically infected in 
the past developed HCC
Aside from current chronic infection (OR 27.9, p=0.001), male sex (OR 4.4, p<0.001) and genotype 3 
rather than genotype 1 infection (OR 2.4, p=0.031), were independently associated with HCC prevalence 
in chronically infected participants on multivariate logistic regression analysis. When source of infection 
was substituted for sex in the model, participants infected through blood transfusions/ treatment for renal 
disease and those infected through clotting factors were significantly more likely to have developed HCC 
compared to those infected through anti-D. 
On Cox multivariate regression analysis participants who remained chronically infected (hazard ratio 28.5, 
p=0.001) (figure 13), those with high alcohol intake (hazard ratio 2.4, p=0.026), males (hazard ratio 4.1, 
p<0.001) and those with genotype 3 HCV infection (compared to genotype 1) (hazard ratio 3.9, p<0.001) 
had higher rates of HCC. When source of infection was substituted for sex in the model, transfusion/
renal and clotting factor participants had higher rates of HCC than anti-D participants and alcohol was no 
longer associated with rate of HCC.
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Figure 13. Proportion of participants who have not developed HCC over the follow-up period by RNA 
status – Kaplan Meier estimates
4.7 Liver-related diagnostic procedures: Liver biopsies, fibroscans, 
ultrasounds, CT scans and MRI scans
Most liver biopsies were carried out in the mid to late 1990s, with much smaller numbers being done in 
more recent years, therefore latest biopsy results alone may not be a good indicator of current disease 
status (figure 14). Disease progression is now more likely to be monitored using less invasive diagnostic 
procedures such as fibroscans, ultrasounds, CT scans, MRI scans and blood tests of liver function. 
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Figure 14. Number of liver-related diagnostic procedures by year and type of procedure for ever 
chronically infected participants
Note: multiple diagnostic procedures were carried out for some patients. Data on ultrasound, CT scans, MRI scans and fibroscans is 
more reliable since 2009, as the method and detail of recording these data has improved significantly since then.
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4.7.1 Liver biopsies
Overall, 1785 biopsies have been carried out on 805 database participants. Ninety seven percent (n=1725) 
had an inflammation grade and 90% (n=1601) had a fibrosis score recorded. Eighty one percent (n=659) 
of chronically infected participants had at least one biopsy with a documented fibrosis score and 83% 
had at least one biopsy with a documented inflammation grade. The likelihood of having a biopsy varied 
by source of infection, with only 42% (n=45) of chronically infected clotting factor participants having 
biopsy results in their charts compared to 97% (n=414) of chronically infected anti-D participants and 
82% (n=224) of those infected through blood transfusions or treatment for renal disease. Since 2009, 106 
biopsies have been carried out on 102 participants, with 20% (n=77) of those who remained chronically 
infected and alive having a recent liver biopsy.
4.7.2 Results of liver biopsies
Inflammation
Twenty nine percent (n=195) of ever chronically infected participants had moderate or severe inflammation 
on last biopsy. Inflammation grade on biopsy varied by source of infection with 34% of chronically infected 
transfusion/renal participants having moderate or severe inflammation on their last biopsy compared to 
27% of anti-D participants and 23% of participants infected through clotting factors. 
Fibrosis
Fibrosis was scored using different scoring systems in different units. Overall 79% of biopsies were scored 
using a 0-6 scoring system, and a 0-4 system was used for the remaining 21%. Biopsy results scored from 
0 to 6 were converted to the 0 to 4 scores (see Methods section 3.10) for some analyses to allow all 
biopsy results to be analysed together. We considered high fibrosis scores to be scores of 4-6 on biopsies 
scored from 0-6 and scores of 3-4 on biopsies scored from 0-4. 
Twenty two percent (n=147) of chronically infected participants had a high fibrosis score on their most 
recent biopsy (where fibrosis score was recorded, n=659). Fibrosis varied by source of infection, with 
33% (n=68) of chronically infected blood transfusion or renal participants having a high fibrosis score 
on most recent biopsy compared to 27% (n=12) of clotting factor participants and 16% (n=66) of anti-D 
participants (figure 15).  
Aside from chronic infection, risk factors independently associated with having a high fibrosis score on 
latest biopsy on logistic regression analysis were: ever having high levels of alcohol consumption (OR 3.2, 
p=0.001), longer duration of RNA positivity at last biopsy  (30+ years compared to <20 years) (OR 2.5, 
p=0.005), older age at last biopsy (55+ compared to less than 55 years) (OR 2.3, p<0.001), male sex (OR 
2.2, p=0.001) and genotype 3 infection (compared to genotype 1 infection) (OR 1.9, p=0.037). When 
source of infection was substituted for sex in the model, participants infected through blood transfusions/ 
treatment for renal disease and those infected through clotting factors were significantly more likely 
to have developed cirrhosis compared to those infected through anti-D and genotype was no longer 
significantly associated with high fibrosis scores on latest biopsy.
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Figure 15. Fibrosis score* on last biopsy for chronically infected participants by source of infection 
(n=659)
*All 0-6 scores standardised to 0-4 (see Methods section 3.10 for description) to allow all biopsies to be analysed together. 
Note: results for clotting factor participants are not representative as data are only available for 44 (41%) and the last biopsy was 
several years ago for many.
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Changes in biopsy results post-treatment
Ninety six chronically infected participants who had pre-treatment biopsy results also had biopsy results at 
least six months after treatment. The changes in fibrosis scores (all standardised to 0 to 4 system) by anti-
viral treatment response are shown in figure 16. Fibrosis scores improved for 59% (n=13) of those who 
achieved a sustained virological response (SVR) on treatment compared to 33% (n=24) of those who did 
not. Scores worsened for 5% (n=1) of those who achieved an SVR and 27% (n=20) of those who did not.
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Figure 16. Changes in fibrosis scores (0-4) after treatment, by SVR status for participants who had 
pre- and post-treatment biopsy results (n=96)
Note: All 0-6 scores standardised to 0-4 (see chapter 3 for description) to allow all biopsies to be analysed together. Numbers in 
some categories are very low and percentages should be interpreted with caution.
4.7.3 Fibroscan results
Fibroscans are increasingly being used to monitor disease progression in the database cohort. Thirty two 
percent (n=126) of the database participants who remained alive and chronically HCV infected at the end 
of latest follow-up had a fibroscan test since 2009. Twenty nine percent of these (n=36) had fibroscan 
results in the cirrhotic or pre-cirrhotic range (table 27) (see Methods section 3.11).
Table 27. Latest fibroscan results for living chronically infected participants by source of infection 
(n=126)
Fibroscan results (kPa) All participants Anti-D all
Transfusion or 
renal
Clotting factors
 Num % Num % Num % Num %
0-7.0 65 51.6 54 57.4 8 40.0 3 25.0
7.1-8.6 18 14.3 9 9.6 5 25.0 4 33.3
8.7-9.4 7 5.6 7 7.4  0.0  0.0
9.5-14.4 23 18.3 16 17.0 6 30.0 1 8.3
14.5+ 13 10.3 8 8.5 1 5.0 4 33.3
 126 100.1 94 99.9 20 100 12 99.9
4.8 Liver function tests, platelets and alpha-fetoprotein (AFP)
Low albumin levels, low platelet counts, elevated AFP levels and elevated ALT and bilirubin levels are all 
associated with cirrhosis and HCC in chronically infected participants. However a significant proportion of 
patients with these conditions may present with normal liver function test results (table 28).
Test data for chronically infected participants were very complete for albumin (99%), AFP (93%), ALT (98%) 
and bilirubin (99%). Platelet data were less complete, with results available for 75% of ever chronically 
infected participants.
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Table 28. Liver function tests, platelets and AFP, by RNA status
Liver function test results
Ever chronically 
infected all
Ever chronically 
infected with 
cirrhosis
Ever chronically 
infected with 
HCC
Never chronically 
infected
 Num % Num % Num % Num %
Albumin         
Normal 599 74.6 79 44.9 13 30.2 408 90.7
Low: <2 times lower normal limit 194 24.2 93 52.8 27 62.8 41 9.1
Low: >2 times lower normal limit 10 1.2 4 2.3 3 7.0 1 0.2
Platelets         
Normal 466 76.9 44 35.8 7 33.3 256 97.0
Low: <2 times lower normal limit 107 17.7 51 41.5 4 19.0 5 1.9
Low: >2 times lower normal limit 33 5.4 28 22.8 10 47.6 3 1.1
AFP         
Normal 587 77.2 80 47.3 8 18.6 352 93.6
 Elevated: <2 times upper normal limit 80 10.5 25 14.8 6 14.0 18 4.8
 Elevated: >2 times upper normal limit 93 12.2 64 37.9 29 67.4 6 1.6
ALT         
Normal 287 36.1 36 20.3 8 18.2 372 83.8
 Elevated: <2.5 times upper normal 
limit
316 39.7 61 34.5 14 31.8 62 14.0
 Elevated: >2.5 times upper normal 
limit
192 24.2 80 45.2 22 50.0 10 2.3
Bilirubin         
Normal 650 80.5 94 55.6 17 39.5 416 91.2
 Elevated: <2 times upper normal limit 95 11.8 30 17.8 10 23.3 34 7.5
 Elevated: >2 times upper normal limit 62 7.7 45 26.6 16 37.2 6 1.3
4.9 Deceased participants
Two hundred and sixty participants had died by latest follow-up. This includes forty eight additional 
deceased participants compared to the previous round of follow-up in 2009. On Cox multivariate 
regression analysis, all-cause mortality (i.e. deaths from any cause) varied significantly by RNA status: 31% 
(n=172) of those whose latest status was recorded as chronic infection were deceased by latest follow-up 
compared to 5% (n=13) of participants who were chronically infected in the past and had since cleared 
the virus (mostly through treatment) (hazard ratio 9.4, p<0.001) (figure 17). Other factors independently 
associated with higher all-cause mortality rates were male sex (hazard ratio 2.2, p<0.001), high alcohol 
intake (hazard ratio 1.9, p=0.003) and genotype 3 compared to genotype 1 infection (hazard ratio 
2.5, p<0.001). When source of infection was substituted for sex in the model, blood transfusion/renal 
participants and clotting factor participants had significantly higher mortality rates than anti-D participants. 
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Figure 17. Proportion of participants who have not died (all-causes) over the follow-up period by RNA 
status – Kaplan Meier estimates
Where death certificates were available (n=237), death was directly caused by liver disease for 73 
participants (table 29) (see Methods section 3.8 regarding coding of deaths). The causes of death for 
these 73 were:
	 •  chronic viral hepatitis C (n=33)
	 •  liver cell carcinoma (n=23)
	 •  liver failure (n=6) 
	 •  cirrhosis of the liver (n=5) 
	 •  unspecified liver cancer (n=1)
	 •  intrahepatic bile duct carcinoma (n=1)
	 •  liver transplant failure and rejection (n=1)
	 •  B-cell lymphoma (n=1)
	 •  chronic viral hepatitis B (n=1)
	 •  toxoplasma hepatitis (n=1) 
HCV infection was one of the causes of death listed on the first part of the death certificate for sixty 
one of the participants who died from liver-related causes. The first part of the death certificate details 
the chain of diseases or conditions leading directly to death. Of the 73 participants who died from 
liver-related causes, 60 were chronically HCV infected at the time of their death, 3 had been chronically 
infected in the past, but had cleared the virus, two were never chronically infected and eight had no RNA 
results in their charts. Table 29 shows further details on the 63 who were ever chronically infected.
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Table 29. Death from liver-related disease in ever chronically infected database participants (with 
univariate chi-square test for differences in prevalence of liver-related death across different categories of 
host and virus variables)
 Ever chronically infected database 
participants
Number who 
died directly 
from liver-
related disease
% of each cohort 
who died directly 
from liver-related 
disease
Median age 
at death 
(years)
Median 
duration RNA 
positivity at 
death (years)
p-value
All 63 7.9 62 27  
Sex     0.001
Females 35 6.0 63 29  
Males 28 12.9 54.5 22.5  
Source of infection     <0.001
Anti-D all 18 4.3 61.5 31.5  
Anti-D 77-79 18 4.9 61.5 31.5  
Anti-D 91-94 0 0    
Transfusion or renal 31 11.6 65 21  
Clotting factors 13 12.4 49 27  
Highest recorded alcohol intake     <0.001
Non drinker 13 7.6 65 22  
Within recommended limits 18 4.0 60 30  
Moderately high 4 7.0 61 32.5  
High 21 29.6 59 26  
BMI     0.316
Normal or underweight 5 3.9 68 32  
Overweight 8 5.3 69 32.5  
Obese 2 1.7 51 36  
Age at end of latest follow-up (years)     0.765
0-49 13 8.6 43 25  
50-64 26 7.1 57 29.5  
65+ 24 8.5 71.5 26.5  
RNA status at latest follow-up     <0.001
Past chronic infection, cleared virus 3 1.2 ~ ~  
Currently chronically infected 60 10.9 61.5 27  
HCV genotype     0.08
Genotype 1 46 7.8 62.5 30  
Genotype 2 6 16.2 68.5 23.5  
Genotype 3 7 5.1 55 23  
~Data on median age and median duration of RNA positivity not presented as only three participants who were chronically infected 
in the past died from liver-related causes
On Cox multivariate regression analysis, liver-related mortality was significantly higher in participants who 
were currently chronically infected with HCV (n=60, 10.9%) compared to those who had been chronically 
infected in the past and had since cleared the virus (mostly through treatment) (n=3, 1.2%) (hazard ratio 
7.9, p=0.001) (figure 18). High alcohol intake (hazard ratio 5.7, p<0.001) and male sex (hazard ratio 2.1, 
p=0.009) were also independently associated with higher liver-related mortality rates. Information on 
alcohol consumption was available for 84% of those whose death was caused by liver disease. Thirty nine 
percent (n=24) had indicators of high levels of alcohol consumption in their medical charts. When source 
of infection was substituted for sex in the model those infected through blood transfusions (hazard ratio 
3.4, p<0.001) or clotting factors (hazard ratio 2.3, p=0.044) were more likely to have died from liver-
related causes than anti-D participants. 
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Figure 18. Proportion of participants who have not died from liver-related causes over the follow-up 
period by RNA status – Kaplan Meier estimates
4.10 Changes in the prevalence of the main liver-related outcomes since 
baseline data were collected
HCV disease progresses particularly after two to four decades of infection.6 The median duration of 
RNA positivity for database participants who became chronically infected is now 31 years (currently RNA 
positive: 34 years, RNA positive in past: 22 years). This is the fifth round of data collection and increases 
can be seen in the prevalence of liver-related health outcomes since baseline data were collected (figure 
19). However, in interpreting the findings on fibrosis scores, it is important to note that few liver biopsies 
have been carried out in recent years.
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Figure 19. Changes in the prevalence of all cause mortality and liver-related outcomes for chronically 
infected participants since baseline data were collected.
Note: Few liver biopsies have been carried out in recent years  
4.11 Anti-viral treatment for hepatitis C
Forty eight percent (n=390) of chronically infected participants had 526 courses of anti-viral treatment by 
latest follow-up. A treatment outcome was available for 504. Participants stopping treatment early are 
included when calculating sustained virological response (SVR). The SVR rate has improved in recent years, 
firstly with the introduction of combination therapy with pegylated interferon (peg-IFN) and ribavirin (RBV) 
and subsequently with the addition of telaprevir (TVR) or boceprevir (BOC) (figure 20). Tolerance of anti-
viral treatment has remained an issue, with 15% (n=34) of treatment courses with peg-IFN and RBV, and 
9% (n=2) of treatment courses with triple therapies stopped early due to side effects. 
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Figure 20.Number of treatment courses by type of treatment and percentage SVR, 1992-2013 
Note: Outcome is awaited for 22 participants (not included when calculating SVR). One treatment course with ribavirin alone and 
one treatment course with faldaprevir and ribavirin also omitted. 
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4.11.1 Treatment response: last treatment, any drug regimen
The participants who were more likely to have been treated were those who were younger, those infected 
in the 1991-1994 anti-D outbreak, or through blood transfusions or clotting factors, those with higher 
fibrosis scores and participants with genotype 2 or 3 infections (table 30). On logistic regression analysis, 
younger participants, those with genotypes 2 or 3, those who were not cirrhotic prior to treatment and 
those who did not have high levels of alcohol intake were more likely to have had an SVR overall. Sex and 
source of infection were not significantly associated with SVR when these other factors were taken into 
account. 
Table 30. Number and percentage of chronically infected participants treated with any drug regimen, 
and percentage SVR, by demographic and virus characteristics
Characteristic
Number of 
participants 
treated - any 
drug regimen
% treated - any 
drug regimen
Number with 
treatment 
outcome
% SVR on last 
treatment - any 
drug regimen
All 390 48.0 368 54.6
Sex     
Female 273 46.2 258 52.7
Male 117 52.7 110 59.1
Source of infection     
Anti-D all 184 43.0 175 52.6
Anti-D 77-79 140 37.4 131 42
Anti-D 91-94 34 91.9 34 91.2
Blood transfusion/renal 144 52.6 137 52.6
Blood clotting factors 60 56.1 55 65.5
Ever had a high fibrosis score on biopsy     
No 224 46.7 212 61.3
Yes 120 67.0 110 37.3
Genotype     
1 249 41.6 229 42.8
2 27 73.0 27 66.7
3 103 72.5 101 75.2
Age at latest follow-up     
0 to 49 years 91 57.6 84 71.4
50 to 64 years 196 53.1 185 54.1
65+ years 103 36.0 99 41.4
Note: Treatment outcome awaited for 22 participants, omitted when calculating SVR. Genotype not available for 9 participants who 
were treated. Two participants with genotype 5 who were treated were omitted from the genotype breakdown in this table. Fibrosis 
scores not available for 46 of the participants who were treated
4.11.2 Treatment response: pegylated interferon and ribavirin
SVR rates for treatment naïve participants on peg-IFN and RBV, by genotype and duration of treatment, 
are shown in figure 21. Seventy five percent (n=21) of genotype 2 or 3 participants on combination 
therapy for 24 weeks or more achieved an SVR compared to 59% (n=34) of genotype 1 participants 
treated for 48 or more weeks (standard of care for genotype 1). 
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Figure 21. Percentage SVR for treatment-naïve participants treated with combination therapy with 
Peg-IFN and RBV (n=159), by genotype and duration of therapy
Sixty one participants were re-treated with peg-IFN and RBV having failed to achieve SVR on previous 
treatment courses with other drug regimens. Their response rate on first re-treatment was 34.4%. 
However, response rates were good for genotype 1 participants whose first re-treatment was for 48 or 
more weeks (50%) and for genotype 2 or 3 participants whose first re-treatment was for 24 or more weeks 
(73%). Response rates by genotype and duration of treatment are shown in figure 22. 
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Figure 22. Percentage SVR for participants  who previously failed to achieve SVR on other drug 
regimens and were re-treated with combination therapy with Peg-IFN and RBV (n=61), by genotype 
and duration of therapy
4.11.3 Treatment response: triple therapies
Twenty eight genotype 1 participants were treated with TVR in combination with Peg-IFN and RBV.  
Treatment response was available for sixteen at the end of latest follow-up. The overall SVR rate was 81% 
(n=13) and all participants treated for 24 weeks or longer achieved an SVR (n=11, 100% SVR) (figure 23). 
The 28 participants treated with this regime included two who were co-infected with HIV. .
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Nine genotype 1 participants were treated with BOC in combination with Peg-IFN and RBV.  Treatment 
response was available for five at the end of latest follow-up. The overall SVR rate was 80% (n=4) and all 
participants treated for 24 weeks or longer achieved an SVR (n=4, 100% SVR) figure 23.
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Figure 23. Percentage SVR for participants treated with BOC or TVR, in combination with Peg-IFN 
and RBV (n=21) by duration of treatment 
4.12 Liver transplants 
Twenty two database participants had received twenty five liver transplants by the end of 2013. Fifteen 
received transplants in 2007 or earlier, three were transplanted in 2008 and one was transplanted each 
year from 2009 to 2012. The median age at transplant was 53.5 years (range: 29-66 years) and the median 
duration of HCV infection at transplant was 29 years (range: 1-39 years). All transplant recipients were 
RNA positive when transplanted and all of those tested post-transplant (n=17) remained RNA positive. Six 
transplant recipients (27%) had evidence of high alcohol consumption at some stage.
Post-transplant biopsy or other staging results were available for twelve participants. Within five years of 
transplant, two developed HCC, five developed cirrhosis, one had moderate or advanced fibrosis, two 
had mild fibrosis and one had no fibrosis. One further participant developed cirrhosis and HCC many 
years after transplant.
Eleven of the liver transplant patients have since died. Five died from liver-related causes, five died from 
non-liver-related causes and no death certificate was available for the remaining patient. The median time 
between transplant and death for these patients was 29 months.
4.13 Medical conditions (relevant conditions only)
Medical conditions recorded in participants’ medical charts were entered into the database.  However, 
these conditions may not have always been diagnosed according to standardised criteria and may not 
be related to HCV infection. Some medical conditions may also be underestimated if patients are treated 
privately and the condition is not discussed with the consultant hepatologist. However, if the condition 
was serious or known to be associated with HCV infection we think it is more likely to have been reported 
and recorded. 
Without a comparison group, it is not possible to determine if the prevalence of these conditions and 
procedures differed from the general population. However, if the condition was strongly associated with 
HCV infection, we would expect to see a significant difference in the prevalence of the condition between 
participants who became chronically infected and those who cleared the virus after acute infection. We 
excluded medical conditions that were known to pre-date HCV infection, but the year the condition was 
diagnosed was not always known.  
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Table 31 shows common medical conditions that differ significantly by HCV RNA status, and other medical 
conditions of interest (i.e. mentioned in literature as associated with HCV, or raised by patient groups). 
The table indicates where there is a statistically significant (p<0.05) difference in the prevalence of the 
condition between participants who were ever chronically infected and those who were not. Differences 
should be interpreted with caution as follow-up was better for chronically infected participants and this 
may have led to a bias in the reporting and recording of medical conditions. It should also be noted that 
the numbers are small for some of these conditions.
Depression was significantly more likely to be recorded in the medical charts of chronically infected 
participants (n=273, 34%) compared to those who never became chronically infected (n=101, 22%). 
Females were more likely to report depression than males after accounting for the effects of RNA status. 
Participants who had received anti-viral treatment were also more likely to have depression recorded in 
their medical charts. Long-term medications for depression, sleep disorders or anxiety were noted in the 
charts of 71% (n=194) of chronically infected participants with depression. 
On logistic regression analysis, fibromyalgia and osteoporosis were significantly more likely to be recorded 
for older chronically infected females.
Table 31. Medical conditions recorded in charts of participants – conditions that differed significantly by 
RNA status, and other conditions of interest*, excluding conditions known to pre-date hepatitis infection
Disease or condition
Chronically 
infected
Never 
chronically 
infected
Statistically 
significant 
difference
Statistically 
significant 
difference in 
females
Statistically 
significant 
difference in 
males
 Num % Num % p-value p-value p-value
Depression 273 33.6 101 22.1 <0.001 <0.001 0.061
Fibromyalgia 107 13.2 46 10 0.101 0.006 0.312
Diabetes mellitus 78 9.6 25 5.5 0.009 0.039 0.476
Dermatitis and eczema 71 8.7 22 4.8 0.01 0.049 0.051
Osteoporosis 71 8.7 16 3.5 <0.001 <0.001 0.357
Anxiety 47 5.8 15 3.3 0.046 0.021 0.782
Malignant skin cancer 34 4.2 5 1.1 0.002 0.003 0.615
 Thrombocytopenia or other 
purpura
18 2.2 2 0.4 0.015 0.025 0.357
Parkinson's Disease 8 1 3 0.7 0.543 0.56 0.683
Ovarian cancer (females only) 6 1 0   0.038  
Non-Hodgkin's Lymphoma 4 0.3 0  0.133 0.232 0.562
*  Data for some conditions, mentioned in literature as associated with HCV, or raised by patient groups, are included even if the 
condition was not commonly reported and no statistically significant difference was seen between ever and never chronically 
infected participants. 
- 56 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Chapter 5. Focus on three individual patient 
groups 
The database population consists of three groups which differ by their source of infection. This chapter 
provides more detail on each of these groups and compares them by characteristics and outcomes. The 
summary tables 1-12 at the beginning of the report provide details of RNA status and outcomes by group.
5.1 Summary and comparison of outcomes in the three groups
Database participants who ever became chronically infected with HCV through blood transfusions or 
treatment for renal disease had the highest prevalence of serious liver disease in spite of having the 
shortest median duration of RNA positivity at the end of latest follow-up. Thirty six percent (n=99) of 
transfusion/renal participants had clinical signs of serious liver disease, including 30% (n=82) with cirrhosis, 
after a median duration of HCV RNA positivity by latest follow-up of 22 years (table 9). The prevalence 
of serious liver disease was also high in participants who were ever chronically infected through clotting 
factors, with 37% (n=39) having clinical signs of serious liver disease and 20% (n=21) diagnosed with 
cirrhosis after a median duration of RNA positivity of 30 years (table 11). Chronically infected anti-D 
participants had better liver-related outcomes overall, with 22% (n=94) having clinical signs of serious liver 
disease, including 18% (n=77) with cirrhosis, after a median duration of RNA positivity of 35 years  
(table 3).
There are several potential explanations for these differences in liver-related outcomes. Firstly, we would 
expect co-morbidities to be high in transfusion/renal participants in general, as many were infected with 
HCV as a result of treatment for serious medical conditions such as cancer. Transfusion/renal participants 
were also slightly older overall when infected with HCV, with a median age at infection of 32 years for ever 
chronically infected participants, compared to 28 years for anti-D participants and 14 years for participants 
infected through clotting factors. Sex may also be a factor as chronically infected female participants have 
a lower prevalence of serious liver-related outcomes than males in spite of having longer durations of 
RNA positivity. Alcohol intake also varies by sex and hence by source of infection, with 13% of chronically 
infected transfusion/renal participants and 16% of chronically infected clotting factor participants 
consuming high levels of alcohol at some stage, compared to 6% of anti-D participants (tables 19, 20, 21).
5.2 Participants infected through anti-D
In spite of having the longest median duration of RNA positivity, database participants infected through 
anti-D have the lowest prevalence of serious liver-related outcomes. This is likely to be attributable, in 
part, to the fact that this group was entirely composed of females who were infected during or after 
pregnancy and who were likely to have been in relatively good health when infected with HCV. Reported 
alcohol consumption was also lower for female database participants. Their median age at infection of 
28 years was younger than that for the transfusion/renal group but significantly older than that for those 
infected through clotting factors. However, the prevalence of clinical signs of serious liver disease has 
increased significantly (from 14% to 23%) in the four years since last follow-up in those infected between 
1977 and 1979.
Anti-D participants infected between 1977 and 1979 have had the lowest uptake of antiviral treatment 
(n=140, 37.4%) (table 30). However treatment uptake has increased significantly in the past four years as 
only 29% were treated by the end of 2009. The overall SVR was 42% (n=55) in participants infected during 
the 1977-79 anti-D outbreak. Treatment uptake in participants infected during the second anti-D outbreak 
(1991-1994) has been extremely high (n=34, 92%). The percentage achieving SVR has also been very high 
(91%), even in comparison with other genotype 3 database participants (67%, n=45). 
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Demographic characteristics, liver-related outcomes and treatment data for participants infected during 
each anti-D outbreak period are shown in table 32.
Table 32. Summary of demographic characteristics, liver-related outcomes and antiviral treatment 
data by anti-D outbreak in chronically infected participants.
Characteristic
 
1977-1979 Anti-D outbreak
1991-1994 Anti-D 
outbreak
Num % Num %
Hepatitis C genotype Genotype 1 Genotype 3
Chronically infected with hepatitis C 374  37  
Median  age at infection (years) 28  30  
Median age at end of follow-up (years) 63  50  
Median years since infection at end of follow-up 36  20  
Mean duration RNA positivity (years) 36  6  
Alcohol intake     
Alcohol data available (highest reported) 366  36  
<14 units per week 328 89.6 30 83.3
15 to 40 units per week 19 5.2 1 2.8
>40 units per week or alcohol abuse in chart 19 5.2 5 13.9
Outcomes     
Signs of liver disease 87 23.3 5 13.5
Cirrhosis 72 19.3 3 8.1
HCC 7 1.9 0 0.0
High fibrosis score on biopsy 83 22.2 2 5.4
Deceased 53 14.2 1 2.7
Liver-related disease directly caused death 18 4.9 0 0.0
Hepatitis C treatment     
Treated 140 37.4 34 91.9
Treated and treatment response available 131 35.0 34 91.9
SVR on peg-IFN & RBV - treatment naïve participants 31 (of 65) 47.7 5 (of 8) 62.5
SVR on peg-IFN & RBV with TVR or BOC 10 (of 13) 76.9   
Overall SVR on last treatment with any drug regimen 55 (of 131) 42.0 31 (of 34) 91.2
5.3 Participants infected through blood transfusions or treatment for renal 
disease
Database participants infected through blood transfusions or treatment for renal disease had a high rate 
of HCV chronicity at diagnosis. RNA results were missing for two, but where results were available, 82% 
(n=274) were chronically infected and 18% (n=61) had cleared the HCV virus by this time (table 10).
The group of participants infected through blood transfusions or treatment for renal disease was the 
only patient cohort with a wide age distribution and significant proportions of both males and females, 
and both genotype 1 and 3 infections. These characteristics facilitate the examination of the host and 
virus characteristics associated with clinical signs of serious liver disease. Logistic regression was used to 
model the factors that were independently and significantly associated with serious liver disease in this 
population (table 33).
High alcohol intake, longer duration of infection, older age at the end of latest follow-up, male sex and 
HCV genotype 3 were all found to be independently associated with clinical signs of serious liver disease 
in chronically infected blood transfusion/renal patients (table 33). The effect of genotype 3 is borderline 
significant as the lower confidence interval is very close to 1.
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Table 33. Factors associated with serious liver disease in chronically infected participants infected 
through blood transfusions/treatment for renal disease - logistic regression model (n=239)
Factors associated with signs of serious liver disease Odds ratio p-value
95% confidence 
interval
Highest recorded alcohol consumption    
Non drinker/within recommended limits/moderately high 1   
High (>40 units per week or alcohol abuse in chart) 3 0.009 1.31 - 6.66
Duration of RNA positivity    
<20 years 1   
20+ years 3.2 0.001 1.63 - 6.25
Age at end of latest follow-up (years)    
0-49 years 1   
50+ years 2.4 0.022 1.13 - 4.96
Sex    
Female 1   
Male 2.1 0.017 1.14 - 3.85
Genotype    
Genotype 1 1   
Genotype 2 0.8 0.632 0.27 - 2.19
Genotype 3 1.9 0.039 1.03 - 3.65
5.4 Participants infected through contaminated blood clotting factors 
Of the 165 database participants infected through blood clotting factors, 65% (n=107) were chronically 
infected with HCV at diagnosis and 22% (n=37) had no RNA results in their charts (figure 24). These 
patients had all died prior to RNA testing. It is likely that they were chronically infected with HCV when 
they died. The remaining 13% (n=21) had RNA results in their charts but had never tested positive. These 
participants showed no signs of serious liver-related disease by latest follow-up (table 12).
Thirty five percent (n=37) of the chronically infected participants, 84% (n=31) of those with no HCV RNA 
results and one participant who never tested RNA positive were co-infected with HIV (figure 24). It was 
difficult to ascertain the true effects of HIV co-infection on HCV disease progression as 68% (n=47) of the 
co-infected participants have died. 
However, 38% (n=26) of those who were HIV positive had clinical signs of serious liver disease by latest 
follow-up compared to 24% (n=18) of those who were HIV negative (figure 24), even though they had a 
shorter median duration of follow-up (25 years compared to 31 years). High alcohol intake was also found 
to be associated with serious liver disease in HIV negative participants. Among HIV negative participants, 
fifty six percent (n=5) with high alcohol consumption were classified as having serious liver disease by 
latest follow-up compared to 20% (n=11) of those who had not had high alcohol intake. The effects of 
alcohol on liver disease severity was much less pronounced and not statistically significant in HIV positive 
participants, with 50% (n=4) of those with high alcohol consumption classified as having serious disease 
compared to 44% (n=14) of those without. However, as alcohol data were not available for all, these data 
comprise small numbers of participants and may not be representative. 
Overall, 74 clotting factor participants had died by latest follow-up (table 11). Forty seven were HIV 
positive and twenty seven were HIV negative. Death certificates were available for 43 of the HIV positive 
and 26 of the HIV negative participants who had died. The underlying cause of death was HIV infection for 
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twelve of those who were HIV positive. A further eight had causes of death relating to immunodeficiency 
and two died from infections, but the term HIV was not specifically mentioned on any of their death 
certificates. The proportion of deaths that were directly liver-related differed between HIV positive (23%, 
n=10) and HIV negative participants (39%, n=10), but this difference was not statistically significant and 
was mainly due to a significant proportion of HIV positive participants dying of HIV-related causes prior 
to the development of effective antiretroviral treatments. Seventeen percent of deaths in clotting factor 
participants were due to haemorrhages.
Sixty (56%) participants chronically infected through blood clotting factors had received anti-viral 
treatment for HCV by latest follow-up (table 30). The percentage treated did not vary significantly by HIV 
status (54% HIV positive, 57% HIV negative). Treatment outcome was available for 55 and the percentage 
who achieved SVR on any drug regimen did not differ significantly by HIV status (61% HIV positive, 68% 
HIV negative achieved SVR).
Twenty nine treatment naïve participants were initially treated using peg-IFN and RBV combination 
therapy. Outcome was available for twenty eight (15 HIV negative and 13 HIV positive) and SVR was 
achieved by 54% of HIV positive participants and 53% of HIV negative participants. The combined (HIV 
positive and negative) response rates on initial treatment with peg-IFN and RBV were 36% (n=5) for 
genotype 1 participants and 69% (n=9) for genotype 2/3 participants. These SVR rates were similar to 
those achieved by participants infected through other means (45% SVR for genotype 1 and 73% for 
genotype 2/3). 
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Figure 24. Summary of hepatitis C infection and disease progression in participants infected through 
clotting factor, by HIV status
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Chapter 6. Conclusion
This report shows the current or last known health status of 1,320 people infected with HCV through 
the administration of blood or blood products in Ireland. The database has a high participation rate of 
77% and allows us to follow the effects of HCV on their health as the population ages and the duration 
of infection increases. More than half the database population are now in their fourth decade since they 
acquired HCV infection. It is clear that those who did not develop chronic HCV infection do not show 
signs of liver-related disease. Among those who developed chronic infection, the majority have not been 
shown to have signs of liver-related disease. However, a significant number have developed serious 
liver disease such as cirrhosis and liver cancer, some of whom have died. There has also been a clear 
progression in the prevalence of adverse health outcomes overall since the last round of data collection 
four years ago. Of the total database population, 390 people were alive and still HCV infected at the end 
of the current data collection period.
The factors found to be associated with liver disease progression in the database participants with 
chronic infection have been well described in the literature: male sex, longer duration of infection, older 
age and high alcohol intake.1,6,10 There is clear evidence from published international sources that heavy 
alcohol use accelerates fibrosis progression and increases the risk of cirrhosis, HCC and end stage liver 
disease.32,33,34 The most important factor in disease progression in the database population was alcohol. 
Participants with high alcohol consumption had five times higher odds of having signs of serious liver 
disease including cirrhosis compared to those without. However, information on alcohol consumption was 
not available for all participants and for many others it had not been recorded in recent years. It would be 
helpful to have up to date information on alcohol intake for all participants.
As in previous reports on the database, genotype 3 has again been found to be independently associated 
with having severe liver disease in this population. Although the analysis has adjusted for factors such as 
duration of infection, alcohol intake, sex, and age, there may be residual confounding in the relationship 
between genotype and outcome - for example, due to inaccuracies in reporting of alcohol intake and 
low data availability for BMI. Therefore, this finding is difficult to interpret. Results published in the 
international literature have been conflicting in relation to the impact of HCV genotypes on fibrosis 
progression, and development of cirrhosis and HCC.35,36,37 
BMI was not shown to be a key factor in disease progression in the database population. However, data 
are available for only half of chronically infected participants and may not be representative of the whole 
group. We continue to encourage better recording of BMI data in the hepatology units.
Fibroscans (measures of liver stiffness) are increasingly being used instead of liver biopsies to monitor liver 
disease progression, particularly in combination with blood biomarkers.13 We hope to report further results 
on these non-invasive diagnostic methods in the next review of the database population.
The rapidly shifting therapeutic landscape for HCV infection, with the arrival of new highly effective drug 
regimens, of shorter duration and fewer side effects, offers a more optimistic future for those who still 
have chronic infection. In Ireland, an early access programme started at the end of 2014 to facilitate rapid 
access to these new treatments for those with greatest clinical need. A National Hepatitis C Treatment 
Programme is being established in the HSE in 2015 to govern the ongoing access to hepatitis C treatment 
on a phased basis. We hope to reflect the impact of these new treatments in the next review of the 
database population in several years’ time.
The ongoing support of participants, support groups and health professionals is essential to the success of 
this database work. Eligible people who are not yet participants in the database may join at any time by 
contacting their hepatology unit. The database project team invites participants, health professionals and 
researchers to contact us with suggestions for further development or improvement of the database, and 
requests for information from the database.
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Glossary of definitions, terms and 
abbreviations
Definitions
Case of hepatitis C for the purpose of this database
Any patient with one or more positive test results for hepatitis C, including positive RNA (PCR), line-
immunoassay (RIBA/INNO-LIA) or EIA results, indeterminate line-immunoassay results and weak positive 
EIA results.
Confirmed positive case of hepatitis C
Any patient who had at least one positive RNA (PCR) result or at least one positive line-immunoassay 
(RIBA/INNO-LIA) result.
Ever hepatitis C RNA positive (PCR positive)
Any patient who had at least one positive RNA (PCR) result
Definition of alcohol use in excess of recommended limits (as per guideline that was current at the 
time of setting up the database)
More than 14 units (standard drinks) per week for females
More than 21 units (standard drinks) per week for males
A standard drink in Ireland (at the time of setting up the database) equals 10gms of alcohol and is equal to 
a half pint of beer or a single measure of spirits or a small glass of wine. The limits of 14 and 21 standard 
drinks (spread out over the week) for women and men respectively are used as a general guide for low risk 
drinking.24 
(Note: Low-risk drinking guidelines have since been revised and are now defined as 11 standard drinks for 
women and 17 standard drinks for men, per week.25)
Terms
Anti-D
Antibodies against rhesus D antigens. A small amount of the baby’s blood can enter the mother’s 
circulation during pregnancy, or larger amounts can enter during delivery. If the mother is negative for 
rhesus proteins and the baby is rhesus positive, the mother produces antibodies against the rhesus D 
antigens. These antibodies can pass through the placenta and damage the baby. The risk of disease is 
higher with subsequent pregnancies with rhesus positive babies. Anti-D immunoglobulin given during or 
after pregnancy prevents this.
Ascites
The accumulation of fluid in the spaces between tissues and organs in the abdominal cavity.
Autoantibody tests
Autoantibody tests detect antibodies, which normally fight infections and other foreign substance within 
the body, but are mistakenly attacking the body’s own cells, tissues or organs.
Blood clotting disorders (as used in this report)
Inherited blood disorders in which there is a defect in a factor essential for the clotting mechanism of the 
blood. These include haemophilia A (deficient in factor VIII), haemophilia B (deficient in factor IX), von 
Willebrand disease (deficient in von Willebrand factor) and deficiencies of factors V, VII or X.
Cirrhosis
Widespread replacement of liver tissue by fibrotic scar tissue and regenerative nodules, leading to 
progressive loss of liver function.
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Confidence interval for an odds ratio
The width of a confidence interval provides a range of plausible values for the odds ratio in the population 
from which the data were sampled and gives an idea of the degree of confidence about the accuracy of an 
odds ratio. 
Database
A systematically arranged collection of computer data, structured so that it can be automatically retrieved 
or manipulated.
Extrahepatic manifestations of hepatitis C
Outside of, or unrelated to, the liver. Extrahepatic manifestations associated with hepatitis C include 
cryoglogulinaemia syndrome, glomerulonephritis, neuropathy, lymphoma, Sjögren syndrome, porphyria 
cutanea tarda, diabetes.
Fibrosis
Liver fibrosis refers to the accumulation of tough fibrous scar tissue in the liver.
Genotype testing
Hepatitis C genotype tests are used to determine which of the genetically distinct types of hepatitis C virus 
are present in the patient’s blood. Hepatitis C genotype is important in predicting response to anti-viral 
therapy. 
Health Amendment Act (HAA) card
The HAA card is given to people who contracted hepatitis C from the administration within the state of 
blood or blood products. They are entitled to a range of services under the Health (Amendment) Act 1996. 
Hepatic encephalopathy
Neuropsychiatric abnormality in the setting of liver failure. It is caused by toxic substances, which are 
normally removed by the liver, travelling in the blood to the brain.
Hepatitis C EIA (Enzyme Immunoassay) /ELISA (Enzyme-Linked Immunosorbent assay)
An assay that detects antibodies to specific hepatitis C antigens in a patient’s blood. The hepatitis C EIA 
test is usually used as an initial screening test for hepatitis C antibodies.
Hepatitis C PCR test (Polymerase Chain Reaction)
Test used to detect the presence of hepatitis C virus RNA (genetic material). A positive PCR result indicates 
an active infection with replicating virus.
Hepatocellular carcinoma (HCC)
Primary malignancy (cancer) of the liver.
Hepatomegaly
Enlarged liver.
Liver biopsy
A liver biopsy is a medical procedure involving the removal of a small piece of liver using a special needle. 
This is then examined under a microscope for signs of liver abnormality.
Liver function tests (LFTs)
Liver function tests are a group of blood tests which provide information about how the patient’s liver is 
functioning and may act as indicators of liver injury.
Mean (average)
The mean is a measure of central value that is used when values are normally distributed. The mean is 
calculated by dividing the sum of all the observations by the total number of observations. 
Median
The median is a measure of central value that is used when values are not normally distributed (skewed 
to one side). The median is obtained by arranging observations from lowest value to highest value and 
picking the middle value (divides the observations in half).
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Multivariate logistic regression
Logistic regression is used to determine if the presence of, or level of, other characteristics affect the 
likelihood of a specific outcome of interest occurring. In a multivariate logistic regression model, each 
factor in the model is adjusted for the effect of the other factors on the outcome.
Odds ratio
The odds ratio is a measure of the odds of an event occurring in one group divided by the odds of it 
occurring in another group. An odds ratio of 1 indicates that the event is equally likely in both groups.
Oesophageal varices
Abnormally dilated and lengthened sub-mucosal veins in the oesophagus. These are usually a consequence 
of portal hypertension and may bleed.
Portal hypertension
High blood pressure in the portal vein that carries blood from the digestive tract to the liver. The most 
common cause is cirrhosis. Consequences can include ascites, hepatic encephalopathy, oesophageal 
varices and splenomegaly.
P-value
In statistics, a result is deemed significant if it is unlikely to have occurred by chance. The p-value is the 
probability of obtaining a result at least as extreme as the result obtained in the analysis, by chance alone. 
A p-value of 0.05 indicates that there was a 5% (or 1 in 20) chance of obtaining the result by chance alone. 
If you are comparing the occurrence of a characteristic in two groups, a low p-value (<0.05) indicates that 
it is likely that there is a true difference in the value of, or odds of the occurrence of a characteristic in the 
two groups.
Recombinant immunoblot assay (RIBA)
An additional test for hepatitis C specific antigens in a patient’s blood. RIBA tests are usually performed 
after a positive EIA result and are used to confirm the presence of antibodies to the hepatitis C virus. A 
positive RIBA result is generally considered confirmation that a patient has been infected with hepatitis C, 
but cannot differentiate between past infection and current infection.
Renal
The term renal refers to the kidney.
Sicca/ Sjögren’s syndrome 
A chronic inflammatory disease that is characterized by dryness of mucous membranes especially 
of the eyes and mouth and by infiltration of the affected tissues by immune cells. There is a strong 
epidemiological association between Sjögren’s syndrome and hepatitis C infection.
Signs of liver disease
In this report, the term “signs of liver disease” refers to clinical signs of serious liver disease and includes 
the following: cirrhosis, HCC, varices, portal hypertension, ascites, decompensated liver disease, 
encephalopathy, splenomegaly, hepatomegaly, hepatosplenomegaly, hypersplenism, hepatopulmonary 
syndrome, hepatic synthetic dysfunction, hepatorenal syndrome and portal gastropathy.
Splenomegaly
Enlarged spleen.
Sustained virological response
The absence of detectable hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay 
with lower limit of detection of 50 IU/ml or less at 24 weeks after the end of treatment. 
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Abbreviations
AFP  Alpha-fetoprotein
ALT  Alanine aminotransferase (a liver enzyme)
Anti-HCV Antibody to hepatitis C virus
BOC  Boceprevir
EIA  Enzyme immunoassay, a screening test for hepatitis C
HAA  Health (Amendment) Act
HCV  Hepatitis C virus
HIV  Human immunodeficiency virus
HPSC   Health Protection Surveillance Centre, formerly known as the National Disease Surveillance Centre
HSE  Health Service Executive
IBTS   Irish Blood Transfusion Service, formerly known as the Blood Transfusion Service Board
PCR  Polymerase chain reaction
RBV  Ribavirin
RIBA  Recombinant immunoblot assay, a more specific hepatitis C test
RNA  Ribonucleic acid
SVR  Sustained virological response
TVR  Telaprevir
WHO  World Health Organization
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Appendix A
Members of the National Hepatitis C Database Steering Committee
Dr Barbara Coughlan, UCD School of Nursing
Ms Joanne Deveney, Positive Action (up to March 2014)
Ms Anne Duffy, Irish Haemophilia Society
Ms Susan Gaughran, Transfusion Positive
Professor John Hegarty, St Vincent’s University Hospital (Alternate: Prof Suzanne Norris,    
St James’s Hospital)
Ms Helena Irish, St James’s Hospital
Ms Maura Long, Transfusion Positive
Mr Mark Murphy, Irish Kidney Association
Ms Niamh Murphy, Health Protection Surveillance Centre
Ms Michele Tait, Hepatitis C National Co-ordinator, Health Service Executive (Chair)
Dr Lelia Thornton, Health Protection Surveillance Centre
Ms Noeleen White, Positive Action (up to March 2014)
Administrative support: Ms Kay Maher, Department of Health 
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Appendix B
Members of the National Hepatitis C Database Scientific and Technical Group
Prof Billy Bourke, Our Lady’s Children’s Hospital, Crumlin 
Prof Garry Courtney, St Luke’s Hospital, Kilkenny
Dr Orla Crosbie, Cork University Hospital
Prof John Crowe, Mater Misericordiae University Hospital
Prof John Hegarty, St Vincent’s University Hospital
Dr John Lee, University College Hospital, Galway
Ms Carol McNulty, St Vincent’s University Hospital
Ms Niamh Murphy, Health Protection Surveillance Centre
Prof Frank Murray, Beaumont Hospital
Dr Niamh Nolan, St Vincent’s University Hospital
Prof Suzanne Norris, St James’s Hospital
Prof Cliona O’Farrelly, Trinity College Dublin
Dr Stephen Stewart, Mater Misericordiae University Hospital
Dr Lelia Thornton, Health Protection Surveillance Centre
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Appendix C Data collection form for fourth round of follow-up
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Appendix D: Biopsy scoring
Fibrosis scoring systems
Score
Original HAI or 
Knodell26
Modified HAI or Modified 
Knodell or Ishak27 or 
Desmet28
Scheuer29
0 No fibrosis No fibrosis None
1 Fibrosis portal 
expansion
Fibrosis expansion of some 
portal areas, with or without 
short fibrous septa
Enlarged, fibrotic portal tracts
2 Fibrosis expansion of most 
portal areas, with or without 
short fibrous septa
Periportal or portal-portal septa with intact 
architecture
3 Bridging fibrosis 
(portal-portal or 
portal-central 
linkage)
Fibrosis expansion of most 
portal areas, with occasional 
portal to portal bridging
Fibrosis with architectural distortion but no 
obvious cirrhosis
4 Cirrhosis Fibrosis expansion of portal 
areas, with marked bridging 
(portal to portal as well as 
portal to central)
Probable or definite cirrhosis
5 Marked bridging with 
occasional nodules 
(incomplete cirrhosis)
6 Cirrhosis, probable or 
definite
The grade of inflammation on biopsy was categorised as:
Normal, mild inflammation, moderate inflammation or severe inflammation
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Appendix E: Contact Information
Support Groups
Transfusion Positive
3 Clanwilliam Square, Dublin 2. Tel: 01-639 8855. Fax: 01-639 8856, 
Website:www.transfusionpositive.ie 
Irish Haemophilia Society
First Floor, Cathedral Court, New St, Dublin 8. Tel:01-657 9900, Fax: 01-657 9901, 
Email: info@haemophilia.ie, Website: www.haemophilia.ie
Irish Kidney Association
Donor House, Block 43a Park West, Dublin 12. Tel: 01-620 5306, Fax: 01-620 5366, Locall: 1890-543 639, 
E-mail: info@ika.ie, Website: www.ika.ie
Specialist Centres
Beaumont Hospital
Hepatology Unit, Beaumont Road, Dublin 9. Tel: 01-809 2220/01-809 3000
Mater Misericordiae University Hospital
Hepatology Unit, 55 Eccles St., Dublin 7. Tel:01-803 2048/01-803 2000
St. James’s Hospital
Hepatology Unit, James’s St., Dublin 8. Tel: 01-410 3417/01-410 3000
St. Vincent’s University Hospital
Hepatology Unit, Elm Park, Dublin 4. Tel: 01-209 4248/01-269 4533
Our Lady’s Children’s Hospital
Hepatology Unit, Crumlin, Dublin 12. Tel: 01-409 6742/01-409 6100          
 
Cork University Hospital
Hepatology Unit, Wilton, Cork. Tel: 021 492 2274/021-454 6400
University College Hospital
Hepatology Unit, Newcastle Road, Galway. Tel: 091-544 370/091-524 222
St. Luke’s Hospital
Hepatology Unit, Kilkenny. Tel: 056-778 5329/056-778 5000
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Liaison Officers
HSE Hepatitis C National Office
Ms Michele Tait, Hepatitis C National Co-ordinator, Mill Lane, Palmerstown, Dublin 20 Tel 01 6201750 / 01 
6201712
HSE Dublin North East
Mr Larry Bathe, Health Service Executive, Primary Care Unit, Railway Street, Navan, Co Meath  Tel: 
046 9076451
HSE South Dublin, Kildare & Wicklow 
Ms Michelle Hayes, Health Service Executive, Mill Lane, Palmerstown, Dublin 20 Tel 01 6201840 
HSE Midlands
Ms Elaine Barry, Primary Care Unit, Health Service Executive, Springfield, Mullingar, Co Westmeath. Tel: 
044 938 4429
HSE Mid-West  
Ms Ellen Rush, Tyone Health Centre, Tyone, Nenagh, Co Tipperary. Tel: 067 46449
HSE-North West
Mr Colin McCann, 1st Floor, County Clinic, St Conal’s Hospital, Letterkenny, Co Donegal. Tel 074 9104698 
 
HSE-West
Mr Richard Broderick, Health Service Executive Primary Care Unit, Merlin Park Regional Hospital, Galway. 
Tel: 091 775673
HSE South East
Ms Anne Bambrick, Primary Care Unit, Health Service Executive, Lacken, Dublin Road, Kilkenny, Co 
Kilkenny. Tel: 056 7784296
 
HSE South
Mr Donal Murphy, Primary Care Unit, HSE South, Floor 3, Block 15, St. Finbarr’s Hospital, Douglas Rd, 
Cork Tel 021-4923833
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Relevant National Agencies
Health Protection Surveillance Centre,
25-27 Middle Gardiner St, Dublin 1. Tel: 01-8765300. Email: hcvdatabase@hpsc.ie
Website: www.hpsc.ie, Database website: www.hcvdatabase.ie
National Centre for Hereditary Coagulation Disorders (NCHCD)
St James’s Hospital, James’s St., Dublin 8. Tel: 01-416 2141
Irish Blood Transfusion Service
National Blood Centre, James’s St., Dublin 8. Tel: 01-432 2800
National Virus Reference Laboratory
UCD, Belfield, Dublin 4. Tel: 01-716 1323
Consultative Council on Hepatitis C
2nd Floor HSE Offices, Mill Lane, Palmerstown, Dublin 20. Tel: 01-620 1708
Email: cchepc@health.irlgov.ie, Website: http://www.consultativecouncilonhepc.ie/
Report prepared by the Health Protection Surveillance Centre 
on behalf of the Consultative Council on Hepatitis C
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